SAN DIEGO, Oct. 21, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to onvansertib for the treatment of patients with chronic myelomonocytic leukemia (CMML).

“CMML remains a difficult-to-treat hematologic malignancy with limited treatment options for patients, and 40-50% of myeloproliferative CMML1 patients harbor RAS-pathway mutations, which are associated with more aggressive disease,” said Mani Mohindru, PhD, President and Chief Executive Officer of Cardiff Oncology. “Receiving Orphan Drug Designation for onvansertib in CMML further validates the therapeutic potential of PLK1 inhibition in cancers with significant unmet need and adds to the growing body of evidence supporting this mechanism across both solid tumors and hematologic malignancies. We believe this designation highlights the broader clinical opportunity for onvansertib as a monotherapy as we continue advancing therapies for patients across cancers where new therapeutic approaches are urgently needed.”

Onvansertib is being evaluated in both company-sponsored and investigator-initiated clinical studies, including a Phase 1 investigator-initiated study in relapsed/refractory CMML. As presented at the 2025 American Society of Hematology (ASH) Annual Meeting, onvansertib was relatively well-tolerated as a monotherapy and demonstrated preliminary efficacy in approximately 40% of myeloproliferative CMML patients in the dose ranging trial. The responses included three patients experiencing clinical benefits (38%), with one each of the following: a 100% platelet response, normalization of White Blood Cells, WBC (baseline WBC count > 50 x 109/L), and spleen response. Additionally, one patient (12.5%) had optimal marrow response with bone marrow blast reduction from 8% to 2% facilitating for allogeneic hematopoietic stem transplant and 3 patients experienced stable disease (38%).

Orphan Drug Designation is granted by the FDA to support the development of therapies intended to treat rare diseases or conditions affecting fewer than 200,000 people in the United States. Benefits of the designation may include tax credits for qualified clinical trials, exemption from certain FDA user fees, and up to seven years of market exclusivity upon regulatory approval. Orphan Drug Designation does not alter the standard regulatory requirements or approval process.

About Onvansertib
Onvansertib is a highly specific, oral PLK1 inhibitor advancing toward a registrational trial in first-line RAS-mutated metastatic colorectal cancer (mCRC). In a randomized Phase 2 trial, onvansertib in combination with FOLFIRI/bevacizumab (first-line standard-of-care) demonstrated dose-dependent improvements in overall response rate and progression-free survival compared to standard-of-care alone, building on findings from a prior Phase 2 trial in second-line RAS-mutated mCRC. Based on these results, the Company has selected the 30 mg dose of onvansertib in combination with FOLFIRI/bevacizumab as the regimen to advance into the planned registrational trial in first-line patients with RAS-mutated mCRC.

Onvansertib is also being evaluated in multiple other cancers through investigator-initiated studies, including metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), triple-negative breast cancer (TNBC), and chronic myelomonocytic leukemia (CMML).

About Chronic Myelomonocytic Leukemia
Chronic myelomonocytic leukemia (CMML) is a rare and aggressive hematologic malignancy characterized by features of both myelodysplastic syndromes and myeloproliferative neoplasms. CMML primarily affects older adults and is associated with poor clinical outcomes, including progressive bone marrow failure and risk of transformation to acute myeloid leukemia (AML). Current treatment options remain limited, highlighting the need for novel targeted therapies that can improve outcomes for patients with this disease.

About Cardiff Oncology, Inc.
Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.

For more information, please visit https://www.cardiffoncology.com.

Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified using words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend” or other similar terms or expressions that concern Cardiff Oncology’s expectations, strategy, plans or intentions. These forward-looking statements are based on Cardiff Oncology’s current expectations and actual results could differ materially. There are several factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; our clinical trials may be suspended or discontinued due to unexpected side effects or other safety risks that could preclude approval of our product candidate; results of preclinical studies or clinical trials for our product candidate could be unfavorable or delayed; our need for additional financing; risks related to business interruptions, including cyber-attacks on our information technology infrastructure, which could seriously harm our financial condition and increase our costs and expenses; uncertainties of government or third party payer reimbursement; dependence on key personnel; limited experience in marketing and sales; substantial competition; uncertainties of patent protection and litigation; dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. There are no guarantees that our product candidate will be utilized or prove to be commercially successful. Additionally, there are no guarantees that future clinical trials will be completed or successful or that our product candidate will receive regulatory approval for any indication or prove to be commercially successful. Investors should read the risk factors set forth in Cardiff Oncology’s Form 10-K for the year ended December 31, 2025, and other periodic reports filed with the Securities and Exchange Commission. While the list of factors presented here is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Forward-looking statements included herein are made as of the date hereof, and Cardiff Oncology does not undertake any obligation to update publicly such statements to reflect subsequent events or circumstances.

Investor Contact:
Candice Masse
astr partners
candice.masse@astrpartners.com

Media Contact:
Amy Bonanno
Lyra Strategic Advisory
abonanno@lyraadvisory.com

1. Carr RM, Vorobyev D, Lasho T, et al. RAS mutations drive proliferative chronic myelomonocytic leukemia via a KMT2A-PLK1 axis. Nat Commun. 2021;12(1):2901. Published 2021 May 18. doi:10.1038/s41467-021-23186-w

CLEARFIELD, Pa., Oct. 21, 2026 (GLOBE NEWSWIRE) — CNB Financial Corporation (“Corporation”) (NASDAQ: CCNE), the parent company of CNB Bank, today announced its earnings for the three and nine months ended September 30, 2026.

Certain comparative financial information for the prior year’s three and nine month periods ended September 30, 2025 has been recast to reflect the Corporation’s adoption of Accounting Standards Update 2025-08, Financial Services – Credit Losses (Topic 326): Purchased Financial Assets. The recast primarily eliminates the recognition of Day 1 provision expense associated with acquired loans and records an allowance for credit losses as of the acquisition date. The adoption had no impact on the economics or cash flows of the acquired assets but affected the timing of credit loss expense recognition. This change is not the result of an error, correction, or restatement of previously issued financial statements, but rather, it enhances comparability among periods presented in accordance with applicable financial reporting guidance. Accordingly, certain comparative amounts presented herein differ from those previously reported for these prior year periods.

Key Financial Trends

  • Earnings – Net income available to common shareholders (“earnings”) was $27.0 million, or $0.91 per diluted share, for the three months ended September 30, 2026, compared to $27.2 million, or $0.91 per diluted share, for the three months ended June 30, 2026, and $18.9 million, or $0.69 per diluted share, for the three months ended September 30, 2025. Earnings for the three months ended September 30, 2026, decreased $244 thousand compared to earnings for the three months ended June 30, 2026, while diluted earnings per share remained unchanged at $0.91.
    • Adjusted earnings for the three months ended September 30, 2025, a non-GAAP measure, were $22.5 million, or $0.82 per diluted share, with adjusted earnings excluding after-tax merger and integration costs (“merger transaction related expenses”) related to the Corporation’s acquisition of ESSA Bancorp, Inc. (“ESSA”).1 Earnings for the three months ended September 30, 2026 increased $4.5 million, or $0.09 per diluted share, compared to adjusted earnings for the three months ended September 30, 2025.
  • Loans – Total loans excluding $124.1 million of syndicated loan balances, or (“Organic Loans”), were $6.5 billion as of September 30, 2026. During the three months ended September 30, 2026, Organic Loans increased by $76.5 million, or 1.19% (4.73% annualized), from June 30, 2026.1 The increase in Organic Loans was primarily driven by growth in commercial real estate and residential real estate loans.
  • Deposits – At September 30, 2026, total deposits were $7.0 billion. During the three months ended September 30, 2026, deposits declined by $32.6 million, or 0.46% (1.83% annualized), compared to June 30, 2026. The third quarter of 2026 included the impact of the Bank’s strategy to exit certain higher cost corporate deposits totaling approximately $76.1 million, with an average interest cost of 3.69%. Excluding the impact of this strategic corporate deposits exit, total deposits increased approximately $43.5 million, or 0.61% (2.44% annualized), compared to the second quarter of 2026. Noninterest-bearing deposits increased for the quarter by $13.5 million, or 1.18% (4.67% annualized), compared to June 30, 2026, primarily driven by additional and expanded treasury management customer relationships.
  • Net Interest Margin – Net interest margin was 3.89% for the three months ended September 30, 2026, compared to 3.88% for the three months ended June 30, 2026. Net interest margin on a fully tax-equivalent basis, a non-GAAP measure, was 3.89% and 3.89%, for the three months ended September 30, 2026 and June 30, 2026, respectively.1 Included in net interest margin on a fully tax-equivalent basis was $2.7 million and $4.8 million of purchase accounting loan accretion for the three months ended September 30, 2026 and June 30, 2026, respectively.
  • Credit Quality – Total nonperforming assets were approximately $56.9 million, or 0.68% of total assets, as of September 30, 2026, compared to $58.4 million, or 0.69% of total assets, as of June 30, 2026. The decrease in nonperforming assets was primarily the result of charge-offs of approximately $1.6 million on one commercial and industrial relationship, as discussed in more detail below.
    • Net loan charge-offs for the three months ended September 30, 2026 were $2.4 million, or 0.14% (annualized) of average total loans and loans held for sale, compared to net loan charge-offs of $1.4 million, or 0.09% (annualized) of average total loans and loans held for sale, during the three months ended June 30, 2026. The increase in net loan charge-offs was primarily the result of charge-offs of approximately $1.6 million on one commercial and industrial relationship, as discussed in more detail below.
  • Capital – Book value per common share was $28.86 and $28.75 at September 30, 2026 and June 30, 2026, respectively. Book value per common share at September 30, 2026 reflects an increase of $0.11, or 0.38%, compared to book value per common share at June 30, 2026. The increase in book value per common share was primarily due to an increase in retained earnings (net of the payment of common and preferred stock dividends), partially offset by a higher accumulated other comprehensive loss, primarily reflecting the after-tax impact of temporary unrealized valuation changes in the Corporation’s available-for-sale investment portfolio due to changes in market yields relative to securities maturity dates, and not from other than temporary impairments.
    • Tangible book value per common share, a non-GAAP measure, was $24.87 and $24.73 as of September 30, 2026 and June 30, 2026, respectively.1 Tangible book value per common share at September 30, 2026 reflects an increase of $0.14, or 0.57%, compared to the tangible book value per common share as of June 30, 2026.1 The increase in tangible book value per common share was partially offset by a higher accumulated other comprehensive loss, primarily reflecting the after-tax impact of temporary unrealized valuation changes in the Corporation’s available-for-sale investment portfolio.

1 This release contains references to certain financial measures that are not defined by U.S. Generally Accepted Accounting Principles (“GAAP”). Management believes that these non-GAAP measures provide a greater understanding of ongoing operations, enhance the comparability of results of operations with prior periods, and reflect the effects of significant gains and charges in the periods presented. A reconciliation of these non-GAAP financial measures is provided in the “Reconciliation of Non-GAAP Financial Measures” section.

Executive Summary

  • Earnings were $27.0 million, or $0.91 per diluted share, for the three months ended September 30, 2026, compared to $27.2 million, or $0.91 per diluted share, for the three months ended June 30, 2026, and $18.9 million, or $0.69 per diluted share, for the three months ended September 30, 2025. Earnings for the three months ended September 30, 2026, decreased $244 thousand compared to earnings for the three months ended June 30, 2026, while diluted earnings per share remained unchanged at $0.91.
    • Adjusted earnings for the three months ended September 30, 2025, a non-GAAP measure, were $22.5 million, or $0.82 per diluted share, with adjusted earnings excluding merger transaction related expenses related to the Corporation’s acquisition of ESSA.1 Earnings for the three months ended September 30, 2026 increased $4.5 million, or $0.09 per diluted share, compared to adjusted earnings for the three months ended September 30, 2025, due to organic growth coupled with the overall impact of the acquisition of ESSA.1
  • Earnings were $80.2 million, or $2.69 per diluted share, for the nine months ended September 30, 2026, compared to $42.2 million, or $1.81 per diluted share, for the nine months ended September 30, 2025.
    • Adjusted earnings for the nine months ended September 30, 2025, a non-GAAP measure, were $47.6 million, or $2.05 per diluted share, with adjusted earnings excluding merger transaction related expenses related to the Corporation’s acquisition of ESSA.1 Earnings for the nine months ended September 30, 2026 increased $32.6 million, or $0.64 per diluted share, compared to adjusted earnings for the nine months ended September 30, 2025, due primarily to the overall impact of the acquisition of ESSA.1
  • At September 30, 2026, loans totaled $6.5 billion, excluding $124.1 million of syndicated loans. Organic Loans increased $76.5 million, or 1.19% (4.73% annualized), compared to June 30, 2026. Organic Loan growth was $83.8 million, or 1.31%, compared to September 30, 2025. The increase in loans for the quarter ended September 30, 2026, compared to the quarter ended June 30, 2026, was primarily driven by increases in commercial real estate and residential real estate loans. The year-over-year growth in loans as of September 30, 2026, compared to September 30, 2025, was primarily driven by growth in the Ridge View Bank and ERIEBANK markets. The year-over-year growth was also significantly impacted by an increased level of commercial real estate (“CRE”) loan prepayments, including full repayments of $71.4 million of CRE loans acquired in 2025 as a result of the ESSA acquisition, and a full payoff of $40.0 million of the Corporation’s largest office building loan related to a CRE property in the BankOnBuffalo division.
    • At September 30, 2026, the syndicated loan portfolio totaled $124.1 million, or 1.87% of total loans, compared to $93.9 million, or 1.44% of total loans, at June 30, 2026 and $71.9 million, or 1.11% of total loans, at September 30, 2025. The increase in syndicated lending balances of $30.2 million compared to June 30, 2026, which includes both new credits as well as additional credit extensions on existing quality borrowers, reflects the Corporation’s continued focus on evaluating the level and composition of its syndicated loan portfolio to ensure it continues to provide strong credit quality and profitable use of excess liquidity, while complementing the Corporation’s loan growth from its in-market customer relationships. The Corporation’s portfolio of syndicated credits includes only commercial and industrial loans and no CRE exposure.
  • At September 30, 2026, total deposits were $7.0 billion. Deposits declined for the quarter by $32.6 million, or 0.46% (1.83% annualized), compared to June 30, 2026. The third quarter of 2026 included the strategic exit of higher cost corporate deposits totaling approximately $76.1 million, with an average interest cost of 3.69%. Excluding the impact of the corporate deposits exit, total deposits increased approximately $43.5 million, or 0.61% (2.44% annualized), compared to the second quarter of 2026. Total deposits increased $147.6 million, or 2.14%, compared to September 30, 2025. The year-over-year growth in deposits as of September 30, 2026, compared to September 30, 2025, was primarily driven by both additional and expanded treasury management customer relationships. Noninterest-bearing deposits increased for the quarter by $13.5 million, or 1.18% (4.67% annualized), compared to June 30, 2026, were also the result of additional and expanded treasury management customer relationships. The $78.0 million in deposits classified as held for sale as of September 30, 2026 are associated with a planned sale of certain customer deposit accounts that are part of a broader strategic initiative to optimize the Corporation’s branch and market footprint following the ESSA acquisition. Additional deposit and liquidity profile details were as follows:
    • At September 30, 2026, the total estimated uninsured deposits for CNB Bank were approximately $2.1 billion, or 30.02% of total CNB Bank deposits. When excluding $22.3 million of affiliate company deposits and $760.4 million of pledged-investment collateralized deposits, adjusted total estimated uninsured deposits as of September 30, 2026 were approximately $1.4 billion, or 19.07% of total CNB Bank deposits.
      • Total estimated uninsured deposits for CNB Bank at June 30, 2026 were approximately $2.1 billion, or approximately 28.83% of total CNB Bank deposits. Excluding $21.2 million of affiliate company deposits and $704.2 million of pledged-investment collateralized deposits, adjusted total estimated uninsured deposits as of June 30, 2026 were approximately $1.3 billion, or approximately 18.73% of total CNB Bank deposits.
    • At September 30, 2026, the Corporation had $221.2 million of cash equivalents held at CNB Bank’s interest-bearing deposit account at the Federal Reserve. These excess funds, when combined with total contingent liquidity resources of $6.2 billion including (i) available borrowing capacity from both the Federal Home Loan Bank of Pittsburgh (“FHLB”) and the Federal Reserve, and (ii) available unused commitments from brokered deposit sources and other third-party funding channels, including previously established lines of credit from correspondent banks, resulted in the total available liquidity sources for the Corporation as of September 30, 2026 of approximately 4.7 times the estimated amount of adjusted uninsured deposit balances discussed above.
  • At September 30, 2026 and June 30, 2026, the Corporation had $164.0 million outstanding in short-term borrowings. The Corporation had $181.6 million outstanding short-term borrowings at September 30, 2025. The decrease in short-term borrowings at September 30, 2026 compared to September 30, 2025 was attributable to the repayment of certain borrowings assumed with the ESSA acquisition.
  • At September 30, 2026, the Corporation’s pre-tax net unrealized losses on the combined portfolios of available-for-sale and held-to-maturity securities totaled $81.9 million, or 8.98% of total shareholders’ equity, compared to $54.8 million, or 6.02% of total shareholders’ equity, at June 30, 2026, and $49.8 million, or 5.81% of total shareholders’ equity, at September 30, 2025. The change in unrealized losses during the third quarter of 2026 compared to the second quarter of 2026, as well as for the quarter ended September 30, 2025, was primarily due to changes in the yield curve, coupled with the Corporation’s scheduled bond maturities, which were all realized at par. Importantly, all regulatory capital ratios for the Corporation would still exceed regulatory “well-capitalized” levels as of September 30, 2026, June 30, 2026, and September 30, 2025 if the net unrealized losses at the respective dates were fully recognized.
  • Total nonperforming assets were $56.9 million, or 0.68% of total assets, as of September 30, 2026, compared to $58.4 million, or 0.69% of total assets, as of June 30, 2026, and were $40.4 million, or 0.49% of total assets, as of September 30, 2025. The decrease of $1.6 million at September 30, 2026 compared to June 30, 2026 was primarily driven by charge-offs related to one commercial and industrial relationship during the third quarter of 2026. After the $1.6 million charge-off at September 30, 2026, the relationship had an outstanding balance of $3.0 million and a related reserve of approximately $2.0 million. The $16.5 million increase in nonperforming assets at September 30, 2026, compared to September 30, 2025, was primarily driven by two previously disclosed relationships: a commercial and industrial relationship totaling $7.2 million and a commercial relationship totaling $6.8 million. Net loan charge-offs for the three months ended September 30, 2026 were $2.4 million, or 0.14% (annualized) of average total loans and loans held for sale, compared to net loan charge-offs of $1.4 million, or 0.09% (annualized) of average total loans and loans held for sale, during the three months ended June 30, 2026, and $957 thousand, or 0.06% (annualized) of average total loans and loans held for sale, during the three months ended September 30, 2025.
  • Pre-provision net revenue (“PPNR”), a non-GAAP measure, was $36.7 million for the three months ended September 30, 2026 and $36.9 million and $27.5 million for the three months ended June 30, 2026 and September 30, 2025, respectively.1 Excluding merger and integration costs, adjusted PPNR was $31.7 million for the three months ended September 30, 2025.1 The quarter-over-quarter change in PPNR was driven by higher non-interest expense, partially offset by an increase in non-interest income. For the three months ended September 30, 2026, the increase in PPNR compared to the three months ended September 30, 2025 was primarily attributable to stronger net interest income and non-interest income, partially offset by higher non-interest expenses. PPNR was $107.8 million for the nine months ended September 30, 2026, compared to $65.0 million for the nine months ended September 30, 2025.1 Excluding merger and integration costs, adjusted PPNR was $71.1 million for the nine months ended September 30, 2025.1 The year-to-date 2026 PPNR when compared to the same year-to-date period in 2025 PPNR, excluding merger and integration costs, reflected increases in net interest income and non-interest income, partially offset by an increase in non-interest expense.

“Earnings of $2.69 per diluted share for the first nine months of 2026 were a record for the Corporation versus comparable periods in any prior years, as we sustained positive operating performance in the third quarter consistent with the first half of 2026,” stated Michael Peduzzi, President and CEO of both the Corporation and CNB Bank. “The expanded revenue base and operating efficiencies realized as a result of the ESSA acquisition in July 2025 have added to the continuing solid performance in our legacy banking divisions across our four-state footprint. We continue to realize qualitative growth from both new and expanded relationships in lending and treasury management activities, and see a sound loan production pipeline and both retail and treasury management deposit growth opportunities entering the fourth quarter. Despite the headwinds of an increased yield curve contributing to increased temporary after-tax unrealized losses on our available-for-sale investment portfolio, we continue to have sustained post-dividend retained earnings to favorably accrete tangible book value as we strive to achieve an acceleration of the post-acquisition earn-back period when compared to our pre-merger model projections. We remain well-positioned from an interest rate risk management position to sustain a positive net interest margin in the current changing interest rate environment. Complementing our core operating activities, we also implemented a tax management strategy to purchase renewable energy tax credits at a discount, and apply them to reduce our income tax expense. Importantly, all of these activities are conducted upon an operating foundation reflecting our ongoing commitment to disciplined underwriting, enterprise risk management and sound controls, and effective but well-secured use of expanded technological capabilities. We are pleased with our current financial position and our sustained earnings momentum.”

Other Balance Sheet Highlights

  • Book value per common share was $28.86, $28.75, and $27.12 at September 30, 2026, June 30, 2026, and September 30, 2025, respectively. Excluding the after-tax impact of merger transaction related expenses, book value per common share was $27.30 at September 30, 2025.1 Book value per common share at September 30, 2026 reflects an increase of $0.11, or 0.38%, compared to book value per common share at June 30, 2026. The increase in book value per common share from June 30, 2026 to September 30, 2026 was primarily due to an increase in retained earnings (net of the payment of common and preferred stock dividends), partially offset by an increase in accumulated other comprehensive loss primarily from the after-tax impact of temporary unrealized valuation changes in the Corporation’s available-for-sale investment portfolio. The increase in book value per common share of $1.56, or 5.71%, from September 30, 2025 to September 30, 2026, when excluding the after-tax impact of merger transaction related expenses, was primarily driven by growth in retained earnings, net of common and preferred stock dividends, partially offset by a higher accumulated other comprehensive loss, primarily reflecting the after-tax impact of temporary unrealized valuation changes in the Corporation’s available-for-sale investment portfolio.1
  • Tangible book value per common share, a non-GAAP measure, was $24.87, $24.73, and $22.76 as of September 30, 2026, June 30, 2026, and September 30, 2025, respectively.1 Excluding the after-tax impact of merger transaction related expenses, tangible book value per common share was $22.94 as of September 30, 2025.1 Tangible book value per common share for September 30, 2026 reflects an increase of $0.14, or 0.57%, compared to tangible book value per common share as of June 30, 2026. Adjusted tangible book value per common share (non-GAAP) increased $1.93, or 8.41%, from September 30, 2025 to September 30, 2026, primarily due to growth in retained earnings, net of common and preferred stock dividends, partially offset by a higher accumulated other comprehensive loss, primarily reflecting the after-tax impact of temporary unrealized valuation changes in the Corporation’s available-for-sale investment portfolio.1

Loan Portfolio Profile

  • As part of its lending policy and credit risk management activities, the Corporation tracks lending exposure by industry classification and type to determine potential risks associated with industry concentrations, and to identify any concentration risk issues that could lead to additional credit loss exposure. An important and recurring part of this process involves the Corporation’s continued measurement and evaluation of its exposure to the office, hospitality, and multifamily industries within its commercial real estate portfolio. Even with the Corporation’s historically sound underwriting protocols and high credit quality standards for borrowers in the commercial real estate industry segments, the Corporation monitors numerous relevant sensitivity elements, including occupancy, loan-to-value, absorption and cap rates, debt service coverage and covenant compliance, and developer/lessor financial strength both in the project and globally. At September 30, 2026, the Corporation had the following key metrics related to its office, hospitality, and multifamily portfolios with such metrics including the impact on the respective portfolios of loans acquired during the third quarter of 2025 from the ESSA acquisition, as well as notable early payoffs of larger CRE credits occurring in the first quarter of 2026 as previously noted:
    • Commercial office loans:
      • There were 140 outstanding loans, totaling $132.0 million, or 1.99% of total loans outstanding;
      • There were two nonaccrual commercial office loans that totaled $2.0 million, or 1.55% of total commercial office loans outstanding;
      • There was one past-due commercial office loan that totaled $202 thousand, or 0.15% of the total commercial office loans outstanding; and
      • The average outstanding balance per commercial office loan was $943 thousand.
    • Commercial hospitality loans:
      • There were 148 outstanding loans, totaling $370.2 million, or 5.59% of total loans outstanding;
      • There were no nonaccrual commercial hospitality loans;
      • There were no past-due commercial hospitality loans; and
      • The average outstanding balance per commercial hospitality loan was $2.5 million.
    • Commercial multifamily loans:
      • There were 331 outstanding loans, totaling $539.7 million, or 8.15% of total loans outstanding;
      • There were two nonaccrual commercial multifamily loans that totaled $721 thousand, or 0.13% of total multifamily loans outstanding;
      • There were four past-due commercial multifamily loans that totaled $2.9 million, or 0.54% of total multifamily loans outstanding; and
      • The average outstanding balance per commercial multifamily loan was $1.6 million.

The Corporation had no commercial office, hospitality or multifamily loan relationships considered by the banking regulators to be high volatility commercial real estate (“HVCRE”) credits. No credits acquired from ESSA were considered HVCRE.

Performance Ratios

  • Annualized return on average equity was 12.09%, 12.65%, and 10.05% for the three months ended September 30, 2026, June 30, 2026 and September 30, 2025, respectively. Excluding the impact of merger transaction related expenses, annualized return on average equity was 11.86% for the three months ended September 30, 2025.1 Annualized return on average equity was 12.38% for the nine months ended September 30, 2026. Annualized return on average equity was 8.93% for the nine months ended September 30, 2025. Excluding the impact of merger transaction related expenses, annualized return on average equity was 9.99% for the nine months ended September 30, 2025.1
  • Annualized return on average tangible common equity, a non-GAAP measure, was 14.39%, 15.20% and 12.03% for the three months ended September 30, 2026, June 30, 2026, and September 30, 2025, respectively.1 Excluding the impact of merger transaction related expenses, annualized return on average tangible common equity was 14.33% for the three months ended September 30, 2025.1 Annualized return on average tangible common equity was 14.84% for the nine months ended September 30, 2026. Annualized return on average tangible common equity was 10.13% for the nine months ended September 30, 2025. Excluding the impact of merger transaction related expenses, annualized return on average tangible common equity was 11.42% for the nine months ended September 30, 2025.1
  • The Corporation’s efficiency ratio was 58.21%, 57.86% and 64.56% for the three months ended September 30, 2026, June 30, 2026 and September 30, 2025, respectively, and 56.53%, 56.14% and 62.97%, respectively, on a fully tax-equivalent basis, a non-GAAP measure.1 Excluding merger and integration costs, the efficiency ratio on a fully tax-equivalent basis was 57.67% for the three months ended September 30, 2025.1 The linked-quarter increase, on a fully tax-equivalent basis, represented an increase of 39 basis points compared to June 30, 2026, primarily driven by higher non-interest expense, as further discussed below. The year-over-year decrease was primarily driven by an increase in net interest income, partially offset by an increase in non-interest expense. The Corporation’s efficiency ratio was 58.35% for the nine months ended September 30, 2026, and 56.65% on a fully tax-equivalent basis, a non-GAAP measure.1 The Corporation’s efficiency ratio was 66.80% for the nine months ended September 30, 2025, and 65.74% on a fully tax-equivalent basis, a non-GAAP measure.1 Excluding merger and integration costs, the efficiency ratio on a fully tax-equivalent basis was 62.68% for the nine months ended September 30, 2025. The year-over-year decrease was primarily driven by higher net interest income, partially offset by higher non-interest expense.

Revenue

  • Total revenue (net interest income plus non-interest income) was $87.8 million for the three months ended September 30, 2026, compared to $87.6 million and $77.7 million for the three months ended June 30, 2026 and September 30, 2025, respectively.
    • Net interest income was $76.3 million for the three months ended September 30, 2026, compared to $76.3 million and $67.1 million for the three months ended June 30, 2026 and September 30, 2025, respectively. Net interest income increased $9.2 million, or 13.67%, for the three months ended September 30, 2026, compared to the three months ended September 30, 2025, primarily reflecting the impact of the ESSA acquisition and growth in the Corporation’s legacy loan portfolio.
    • Net interest margin was 3.89%, 3.88%, and 3.69% for the three months ended September 30, 2026, June 30, 2026, and September 30, 2025, respectively. Net interest margin on a fully tax-equivalent basis, a non-GAAP measure, was 3.89%, 3.89% and 3.69% for the three months ended September 30, 2026, June 30, 2026, and September 30, 2025, respectively.1 Excluding the $2.7 million, $4.8 million, and $3.4 million in purchase accounting loan accretion realized in the third quarter of 2026, second quarter of 2026, and third quarter of 2025, respectively, the net interest margin on a fully tax-equivalent basis for the three months ended September 30, 2026, June 30, 2026, and September 30, 2025, was 3.75%, 3.65%, and 3.50%, respectively.1
      • The yield on earning assets of 5.85% for the three months ended September 30, 2026 decreased 3 basis points compared to the three months ended June 30, 2026 and decreased 11 basis points compared to the three months ended September 30, 2025. The decrease in yield in the third quarter of 2026 compared to the quarter ended June 30, 2026 was primarily attributable to a decrease in purchase accounting loan accretion. The decrease in yield during the third quarter of 2026 compared to the third quarter of 2025 was primarily attributable to lower average loan yields resulting from the Federal Reserve interest rate decreases during 2025.
      • The cost of interest-bearing liabilities was 2.48% for the three months ended September 30, 2026, reflecting decreases of 2 basis points and 35 basis points from the three months ended June 30, 2026 and the three months ended September 30, 2025, respectively. The decrease in the cost of interest-bearing liabilities is primarily the result of the Corporation’s targeted interest-bearing deposit rate decreases.
  • Total revenue was $258.8 million for the nine months ended September 30, 2026 compared to $195.8 million for the nine months ended September 30, 2025.
    • Net interest income was $226.0 million for the nine months ended September 30, 2026 compared to $167.8 million for the nine months ended September 30, 2025. When comparing the nine months ended September 30, 2026 to the nine months ended September 30, 2025, the increase in net interest income of $58.2 million, or 34.70% (46.40% annualized), was primarily due to the impact of the ESSA acquisition and growth in the Corporation’s legacy loan portfolio.
    • Net interest margin was 3.87% and 3.57% for the nine months ended September 30, 2026 and September 30, 2025, respectively. Net interest margin on a fully tax-equivalent basis, a non-GAAP measure, was 3.87% and 3.56% for the nine months ended September 30, 2026 and September 30, 2025, respectively.1 Excluding the $10.6 million and $3.4 million in purchase accounting loan accretion realized for the nine months ended September 30, 2026 and 2025, respectively, the net interest margin on a fully tax-equivalent basis was 3.69% and 3.49%, respectively.1
      • The yield on earning assets of 5.86% for the nine months ended September 30, 2026 decreased 1 basis point from September 30, 2025. The decrease in yield compared to September 30, 2025 was attributable to Federal Reserve interest rate decreases since mid-September 2025 until the most recent Federal Reserve rate increase in September 2026, partially offset by growth in higher-yielding securities.
      • The cost of interest-bearing liabilities of 2.50% for the nine months ended September 30, 2026 favorably decreased by 38 basis points from September 30, 2025, primarily the result of the Corporation’s targeted interest-bearing deposit rate decreases in response to the Federal Reserve rate decreases, coupled with the benefit of ESSA’s lower overall interest cost of deposits.
  • Total non‑interest income was $11.5 million for the three months ended September 30, 2026, compared to $11.3 million and $10.6 million for the three months ended June 30, 2026 and September 30, 2025, respectively. The quarter-over-quarter increase was primarily attributable to an increase in wealth and asset management fees and treasury management fees, partially offset by a decrease in net realized and unrealized gains on equity securities and gains from recoveries of acquired loans. The primary increase in wealth and asset management fees was due to a $1.1 million transition fee for the Corporation moving its existing retail investment business platform to a new provider. The year-over-year increase in non-interest income was primarily driven by increases in wealth and asset management fees, including the platform provider change transition fee, treasury management fees, and card processing and interchange income, partially offset by lower net realized and unrealized gains on equity securities and a decrease in net realized gains on available-for-sale securities.
  • Total non-interest income was $32.8 million for the nine months ended September 30, 2026 compared to $28.1 million for the nine months ended September 30, 2025. This increase was primarily due to higher wealth and asset management fees (including the transition fee), treasury management fees, card processing and interchange income, mortgage banking income, and service charges on deposits, partially offset by lower pass-through income from small business investment companies (“SBICs”).

Non-Interest Expense

  • For the three months ended September 30, 2026, June 30, 2026, and September 30, 2025, total non‑interest expense was $51.1 million, $50.7 million, and $50.2 million, respectively. Excluding merger and integration costs, total non‑interest expense for the three months ended September 30, 2025 was $46.0 million.1 The quarter-over-quarter increase of $396 thousand, or 0.78%, was primarily driven by increases in salaries and benefits, partially offset by decreases in legal, professional, and examination fees and other non-interest expenses, including the timing of business development-related costs and other real estate owned expenses. The increase in salaries and benefits was driven primarily by an increase in incentive compensation accruals. The decrease in legal, professional, and examination fees was driven by the reversal of a legal accrual assumed as part of the ESSA acquisition. Excluding merger and integration costs, the $5.1 million, or 11.09%, increase in non-interest expense compared to the three months ended September 30, 2025 was primarily attributable to personnel, software licensing expenses, higher core system volume-based fees, and other operating costs associated with the ESSA acquisition.
  • For the nine months ended September 30, 2026, total non-interest expense was $151.0 million compared to $130.8 million for the nine months ended September 30, 2025. Excluding merger and integration costs, total non‑interest expense for the nine months ended September 30, 2025 was $124.8 million.1 Excluding merger and integration costs, the increase of $26.2 million, or 21.02%, compared to the nine months ended September 30, 2025, was primarily attributable to higher personnel, occupancy and facilities costs, software licensing expenses, increased core system volume-based fees, and other operating costs associated with the ESSA acquisition.

Income Taxes

  • Income tax expense for the three months ended September 30, 2026 was $5.2 million, representing a 15.53% effective tax rate, compared to $6.9 million, representing a 19.50% effective tax rate, for the three months ended June 30, 2026, and $5.5 million, representing a 21.51% effective tax rate, for the three months ended September 30, 2025. Income tax expense for the three months ended September 30, 2026 included the recognition of $1.2 million in renewable energy tax credits. Income tax expense for the nine months ended September 30, 2026 was $18.1 million, representing a 17.84% effective tax rate (including the benefit of the renewable energy tax credits), compared to $11.6 million, representing a 20.39% effective tax rate, for the nine months ended September 30, 2025.

Asset Quality

  • Total nonperforming assets were $56.9 million, or 0.68% of total assets, as of September 30, 2026, compared to $58.4 million, or 0.69% of total assets, as of June 30, 2026, and $40.4 million, or 0.49% of total assets, as of September 30, 2025, as discussed in more detail above.
  • The allowance for credit losses measured as a percentage of total loans was 1.04% as of September 30, 2026, June 30, 2026, and September 30, 2025, respectively. In addition, the allowance for credit losses as a percentage of nonaccrual loans was 127.89% as of September 30, 2026, compared to 123.00% and 187.94% as of June 30, 2026 and September 30, 2025, respectively.
  • The provision for credit losses was $3.5 million for the three months ended September 30, 2026, compared to $1.8 million for the three months ended June 30, 2026, and $2.1 million for the three months ended September 30, 2025. The $1.7 million quarter-over-quarter increase in the provision for credit losses was primarily driven by a $1.6 million charge-off on one commercial loan relationship, as discussed in more detail above. The $1.4 million increase compared to the three months ended September 30, 2025, was primarily attributable to the $1.6 million charge-off on one commercial loan relationship, as discussed in more detail above. The provision for credit losses was $6.2 million for the nine months ended September 30, 2026, compared to $8.0 million for the nine months ended September 30, 2025. The $1.7 million decrease in the provision for credit losses compared to the nine months ended September 30, 2025, was primarily attributable to lower net loan charge-offs.
  • As discussed in more detail above, for the three months ended September 30, 2026, net loan charge-offs were $2.4 million, or 0.14% (annualized) of average total loans and loans held for sale, compared to $1.4 million, or 0.09% (annualized) of average total loans and loans held for sale, during the three months ended June 30, 2026, and $957 thousand, or 0.06% (annualized) of average total loans and loans held for sale, during the three months ended September 30, 2025. Net loan charge-offs were $4.7 million, or 0.10% (annualized) for the nine months ended September 30, 2026, compared to $5.7 million, or 0.15% (annualized) for the nine months ended September 30, 2025.

Capital

  • As of September 30, 2026, the Corporation’s total shareholders’ equity was $912.6 million, representing an increase of $3.1 million, or 0.34%, from June 30, 2026, and an increase of $55.4 million, or 6.47%, from September 30, 2025. The quarter-over-quarter increase was primarily driven by growth in retained earnings of $21.4 million, net of the payment of common and preferred stock dividends, partially offset by a $19.3 million increase in accumulated other comprehensive loss. The year-over-year increase was primarily driven by a $77.6 million increase in retained earnings, net of the payment of common and preferred stock dividends, partially offset by a $25.3 million increase in accumulated other comprehensive loss, during the twelve months ended September 30, 2026.
  • Regulatory capital ratios for the Corporation continue to exceed regulatory “well-capitalized” levels as of September 30, 2026, consistent with prior periods.
  • As of September 30, 2026, the Corporation’s ratio of common shareholders’ equity to total assets was 10.19% compared to 10.10% at June 30, 2026 and 9.66% at September 30, 2025. As of September 30, 2026, June 30, 2026, and September 30, 2025, the Corporation’s ratio of tangible common equity to tangible assets, a non-GAAP measure, was 8.91%, 8.81%, and 8.24%, respectively.1 Excluding merger transaction related expenses, the Corporation’s ratio of tangible common equity to tangible assets, a non-GAAP measure, as of September 30, 2025 was 8.30%.1 The increase in the ratio of tangible common equity to tangible assets compared to September 30, 2025 was primarily the result of an increase in retained earnings (net of the payment of common and preferred stock dividends), partially offset with an increase in accumulated other comprehensive loss.

Conference Call

The Corporation will host an earnings conference call on Thursday, October 29, 2026 at 1:00 p.m. Eastern Time. The direct dial number for the call is (877) 270-2148. Participants should ask to join the CNB Financial Corporation earnings conference call. For those unable to participate in the conference call, a replay will be available. To access the replay, please dial (855) 669-9658 using the access code 9257616, from two hours after the end of the call until November 12, 2026. The conference call, as well as the replay, are also available (listen-only) by internet webcast at https://cnbbank.q4ir.com/events-and-presentations/events.

About CNB Financial Corporation

CNB Financial Corporation is a financial holding company with consolidated assets of approximately $8.4 billion. CNB Financial Corporation conducts business primarily through its principal subsidiary, CNB Bank. CNB Bank is a full-service bank engaging in a full range of banking activities and services, including trust and wealth management services, for individual, business, governmental, and institutional customers. CNB Bank operations include a private banking division, and 79 offices comprised of one loan production office, one mobile office, two limited-service offices, and 75 full-service offices in Pennsylvania, Ohio, New York, and Virginia. CNB Bank, headquartered in Clearfield, Pennsylvania, with offices in Central and North Central Pennsylvania, serves as the multi-brand parent to various divisions. These divisions include ERIEBANK, based in Erie, Pennsylvania, with offices in Northwest Pennsylvania and Northeast Ohio; FCBank, based in Columbus, Ohio, with offices in Central Ohio; BankOnBuffalo, based in Buffalo, New York, with offices in Western New York; Ridge View Bank, based in Roanoke, Virginia, with offices in the Southwest Virginia region; and ESSA Bank, based in Stroudsburg, Pennsylvania, with offices in Northeast Pennsylvania, including the Lehigh Valley region. Additional information about CNB Financial Corporation may be found at www.CNBBank.bank.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, with respect to the Corporation’s financial condition, liquidity, results of operations, future performance and business. These forward-looking statements are intended to be covered by the safe harbor for “forward-looking statements” provided by the Private Securities Litigation Reform Act of 1995. Forward-looking statements are those that are not historical facts. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, estimates and intentions that are subject to significant risks and uncertainties and are subject to change based on various factors (some of which are beyond the Corporation’s control). Forward-looking statements often include the words “believes,” “expects,” “anticipates,” “estimates,” “forecasts,” “intends,” “plans,” “targets,” “potentially,” “probably,” “projects,” “outlook” or similar expressions or future conditional verbs such as “may,” “will,” “should,” “would” and “could.” The Corporation’s actual results may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Such known and unknown risks, uncertainties and other factors that could cause the actual results to differ materially from the statements, include, but are not limited to, (i) adverse changes or conditions in capital and financial markets, including actual or potential stresses in the banking industry; (ii) changes in interest rates; (iii) the credit risks of lending activities, including our ability to estimate credit losses and the allowance for credit losses, as well as the effects of changes in the level of, and trends in, loan delinquencies and write-offs; (iv) effectiveness of our data security controls in the face of cyber attacks and any reputational risks following a cybersecurity incident; (v) changes in general business, industry or economic conditions or competition; (vi) changes in any applicable law, rule, regulation, policy, guideline or practice governing or affecting financial holding companies and their subsidiaries or with respect to tax or accounting principles or otherwise; (vii) adverse economic effects from international trade disputes, including threatened or implemented tariffs imposed by the U.S. and threatened or implemented tariffs imposed by foreign countries in retaliation, or similar events impacting economic activity; (viii) higher than expected costs or other difficulties related to integration of combined or merged businesses; (ix) the effects of business combinations and other acquisition transactions, including the inability to realize our loan and investment portfolios; (x) changes in the quality or composition of our loan and investment portfolios; (xi) adequacy of loan loss reserves; (xii) increased competition; (xiii) loss of certain key officers; (xiv) deposit attrition; (xv) rapidly changing technology; (xvi) unanticipated regulatory or judicial proceedings and liabilities and other costs; (xvii) changes in the cost of funds, demand for loan products or demand for financial services; and (xviii) other economic, competitive, governmental or technological factors affecting our operations, markets, products, services and prices. Such developments could have an adverse impact on the Corporation’s financial position and results of operations. For more information about factors that could cause actual results to differ from those discussed in the forward-looking statements, please refer to the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of and the forward-looking statement disclaimers in the Corporation’s annual and quarterly reports filed with the Securities and Exchange Commission.

The forward-looking statements are based upon management’s beliefs and assumptions and are made as of the date of this press release. Factors or events that could cause the Corporation’s actual results to differ may emerge from time to time, and it is not possible for the Corporation to predict all of them. The Corporation undertakes no obligation to publicly update or revise any forward-looking statements included in this press release or to update the reasons why actual results could differ from those contained in such statements, whether as a result of new information, future events or otherwise, except to the extent required by law. In light of these risks, uncertainties and assumptions, the forward-looking events discussed in this press release might not occur and you should not put undue reliance on any forward-looking statements.

 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
       
  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Income Statement                  
Interest and fees on loans $ 103,943     $ 102,336     $ 98,092     $ 307,606     $ 245,879  
Interest and dividends on securities and cash and cash equivalents   11,054       13,320       10,553       35,085       30,916  
Interest expense   (38,692 )     (39,312 )     (41,516 )     (116,719 )     (109,038 )
Net interest income   76,305       76,344       67,129       225,972       167,757  
Provision for credit losses   3,471       1,777       2,069       6,246       7,963  
Net interest income after provision for credit losses   72,834       74,567       65,060       219,726       159,794  
Non-interest income                  
Wealth and asset management fees   3,672       2,728       2,359       8,757       6,264  
Service charges on deposit accounts   2,144       2,010       2,222       6,188       5,592  
Other service charges and fees   464       417       480       1,303       1,417  
Net realized gains on available-for-sale securities   —       —       397       331       397  
Net realized and unrealized gains (losses) on equity securities   3       707       664       621       982  
Mortgage banking   437       269       196       1,047       464  
Bank owned life insurance   1,046       1,167       975       3,199       2,711  
Card processing and interchange income   2,840       2,804       2,336       8,230       6,721  
Other non-interest income   883       1,200       937       3,113       3,533  
Total non-interest income   11,489       11,302       10,566       32,789       28,081  
Non-interest expenses                  
Salaries and benefits   24,705       22,712       23,339       72,400       63,251  
Net occupancy expense of premises   4,987       5,085       4,823       15,521       12,893  
Technology expense   7,417       7,205       5,485       21,803       16,325  
Amortization of core deposit intangible   1,025       1,016       780       3,046       813  
Advertising expense   662       728       754       2,178       1,824  
State and local taxes   1,849       2,046       1,292       4,716       3,885  
Legal, professional, and examination fees   1,145       1,718       1,637       3,635       3,483  
FDIC insurance premiums   1,255       1,021       940       3,083       2,862  
Card processing and interchange expenses   1,453       1,470       1,300       4,430       3,713  
Merger and integration costs   —       —       4,155       —       6,041  
Other non-interest expense   6,606       7,707       5,652       20,187       15,722  
Total non-interest expenses   51,104       50,708       50,157       150,999       130,812  
Income before income taxes   33,219       35,161       25,469       101,516       57,063  
Income tax expense   5,158       6,857       5,479       18,115       11,636  
Net income   28,061       28,304       19,990       83,401       45,427  
Preferred stock dividends   1,076       1,075       1,076       3,226       3,226  
Net income available to common shareholders $ 26,985     $ 27,229     $ 18,914     $ 80,175     $ 42,201  
                   
Ending shares outstanding   29,620,028       29,621,999       29,477,429       29,620,028       29,477,429  
Average diluted common shares outstanding   29,533,350       29,492,359       27,280,298       29,490,121       23,075,450  
Diluted earnings per common share $ 0.91     $ 0.91     $ 0.69     $ 2.69     $ 1.81  
Adjusted diluted earnings per common share (non-GAAP) (1) $ 0.91     $ 0.91     $ 0.82     $ 2.69     $ 2.05  
Cash dividends per common share $ 0.19     $ 0.19     $ 0.18     $ 0.57     $ 0.54  
Dividend payout ratio   21 %     21 %     26 %     21 %     30 %
Adjusted dividend payout ratio (non-GAAP) (1)   21 %     21 %     22 %     21 %     26 %
                                       

 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
       
  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Average Balances                  
Total loans and loans held for sale $ 6,564,103     $ 6,461,656     $ 5,983,731     $ 6,501,582     $ 5,086,204  
Investment securities   926,156       940,950       843,441       929,894       815,050  
Total earning assets   7,785,804       7,883,060       7,221,656       7,810,301       6,286,016  
Total assets   8,387,702       8,475,376       7,798,867       8,409,827       6,757,473  
Noninterest-bearing deposits   1,169,691       1,153,386       1,078,091       1,149,662       909,597  
Interest-bearing deposits   5,940,381       6,031,354       5,477,057       5,972,370       4,873,469  
Shareholders’ equity   920,710       897,293       789,266       900,500       680,200  
Tangible common shareholders’ equity (non-GAAP) (1)   744,142       718,670       623,654       722,233       556,861  
                   
Average Yields (annualized)                  
Total loans and loans held for sale   6.31 %     6.38 %     6.52 %     6.35 %     6.48 %
Investment securities   3.42 %     3.47 %     2.89 %     3.37 %     2.83 %
Total earning assets   5.85 %     5.88 %     5.96 %     5.86 %     5.87 %
Interest-bearing deposits   2.40 %     2.42 %     2.75 %     2.43 %     2.82 %
Interest-bearing liabilities   2.48 %     2.50 %     2.83 %     2.50 %     2.88 %
                   
Performance Ratios (annualized)                  
Return on average assets   1.33 %     1.34 %     1.02 %     1.33 %     0.90 %
Adjusted return on average assets (non-GAAP) (1)   1.33 %     1.34 %     1.20 %     1.33 %     1.01 %
Return on average equity   12.09 %     12.65 %     10.05 %     12.38 %     8.93 %
Adjusted return on average equity (non-GAAP) (1)   12.09 %     12.65 %     11.86 %     12.38 %     9.99 %
Return on average tangible common equity (non-GAAP) (1)   14.39 %     15.20 %     12.03 %     14.84 %     10.13 %
Adjusted return on average tangible common equity (non-GAAP) (1)   14.39 %     15.20 %     14.33 %     14.84 %     11.42 %
Net interest margin, fully tax equivalent basis (non-GAAP) (1)   3.89 %     3.89 %     3.69 %     3.87 %     3.56 %
Efficiency ratio, fully tax equivalent basis (non-GAAP) (1)   56.53 %     56.14 %     62.97 %     56.65 %     65.74 %
                   
Net Loan Charge-Offs                  
CNB Bank net loan charge-offs $ 2,172     $ 1,135     $ 623     $ 3,827     $ 4,397  
Holiday Financial net loan charge-offs   181       308       334       853       1,302  
Total Corporation net loan charge-offs $ 2,353     $ 1,443     $ 957     $ 4,680     $ 5,699  
Annualized net loan charge-offs / average total loans and loans held for sale   0.14 %     0.09 %     0.06 %     0.10 %     0.15 %
                                       

 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
           
  September 30,
2026
  June 30,
2026
  September 30,
2025
Ending Balance Sheet          
Cash and due from banks $ 96,962     $ 86,618     $ 79,772  
Interest-bearing deposits with Federal Reserve   221,181       364,781       351,943  
Interest-bearing deposits with other financial institutions   7,202       7,040       6,373  
Total cash and cash equivalents   325,345       458,439       438,088  
Debt securities available-for-sale, at fair value   677,435       692,513       533,553  
Debt securities held-to-maturity, at amortized cost   185,863       203,049       249,247  
Equity securities   11,745       11,682       10,505  
Loans held for sale   1,098       1,855       —  
Loans receivable          
Syndicated loans   124,085       93,859       71,852  
Loans   6,496,541       6,420,002       6,412,731  
Total loans receivable   6,620,626       6,513,861       6,484,583  
Less: allowance for credit losses   (68,573 )     (67,455 )     (67,684 )
Net loans receivable   6,552,053       6,446,406       6,416,899  
Goodwill and other intangibles   87,465       87,465       93,773  
Core deposit intangible   30,646       31,672       34,727  
Other assets   513,467       499,088       493,914  
Total Assets $ 8,385,117     $ 8,432,169     $ 8,270,706  
           
Noninterest-bearing demand deposits $ 1,161,425     $ 1,147,907     $ 1,105,414  
Interest-bearing demand deposits   1,047,255       1,023,540       970,752  
Savings   3,727,696       3,762,710       3,686,511  
Certificates of deposit   1,111,491       1,146,307       1,137,590  
Total deposits   7,047,867       7,080,464       6,900,267  
Short-term borrowings   164,000       164,000       181,604  
Subordinated debentures   20,620       20,620       20,620  
Subordinated notes, net of issuance costs   35,000       35,000       84,798  
Deposits held for sale   77,966       81,303       92,830  
Other liabilities   127,114       141,335       133,457  
Total liabilities   7,472,567       7,522,722       7,413,576  
Common stock   —       —       —  
Preferred stock   57,785       57,785       57,785  
Additional paid in capital   425,553       424,486       421,770  
Retained earnings   488,222       466,865       410,612  
Treasury stock   (3,165 )     (3,129 )     (2,476 )
Accumulated other comprehensive loss   (55,845 )     (36,560 )     (30,561 )
Total shareholders’ equity   912,550       909,447       857,130  
Total liabilities and shareholders’ equity $ 8,385,117     $ 8,432,169     $ 8,270,706  
           
Book value per common share $ 28.86     $ 28.75     $ 27.12  
Adjusted book value per common share (non-GAAP) (1) $ 28.86     $ 28.75     $ 27.30  
Tangible book value per common share (non-GAAP) (1) $ 24.87     $ 24.73     $ 22.76  
Adjusted tangible book value per common share (non-GAAP) (1) $ 24.87     $ 24.73     $ 22.94  
                       

 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
           
  September 30,
2026
  June 30,
2026
  September 30,
2025
Capital Ratios          
Tangible common equity / tangible assets (non-GAAP) (1)   8.91 %     8.81 %     8.24 %
Adjusted tangible common equity / tangible assets (non-GAAP) (1)   8.91 %     8.81 %     8.30 %
Tier 1 leverage ratio (2)   10.57 %     10.19 %     9.34 %
Common equity tier 1 ratio (2)   12.19 %     12.02 %     10.48 %
Tier 1 risk-based ratio (2)   13.37 %     13.23 %     11.67 %
Total risk-based ratio (2)   14.67 %     14.53 %     13.97 %
           
Asset Quality Detail          
Nonaccrual loans $ 53,618     $ 54,842     $ 36,013  
Loans 90+ days past due and accruing   99       27       86  
Total nonperforming loans   53,717       54,869       36,099  
Other real estate owned and repossessed assets   3,140       3,554       4,254  
Total nonperforming assets $ 56,857     $ 58,423     $ 40,353  
           
Asset Quality Ratios          
Nonperforming assets / Total loans + OREO   0.86 %     0.90 %     0.62 %
Nonperforming assets / Total assets   0.68 %     0.69 %     0.49 %
Ratio of allowance for credit losses on loans to nonaccrual loans   127.89 %     123.00 %     187.94 %
Allowance for credit losses / Total loans   1.04 %     1.04 %     1.04 %
           
           
           
           
Consolidated Financial Data Notes:          
(1) Management uses non-GAAP financial information in its analysis of the Corporation’s performance. Management believes that these non-GAAP measures provide a greater understanding of ongoing operations, enhance comparability of results of operations with prior periods and show the effects of significant gains and charges in the periods presented. The Corporation’s management believes that investors may use these non-GAAP measures to analyze the Corporation’s financial performance without the impact of unusual items or events that may obscure trends in the Corporation’s underlying performance. This non-GAAP data should be considered in addition to results prepared in accordance with GAAP, and is not a substitute for, or superior to, GAAP results. Limitations associated with non-GAAP financial measures include the risks that persons might disagree as to the appropriateness of items included in these measures and that different companies might calculate these measures differently. A reconciliation of these non-GAAP financial measures is provided below (dollars in thousands, except per share data).
(2) Capital ratios as of September 30, 2026 are estimated pending final regulatory filings.
 

 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
   
  Average Balances, Income and Interest Rates on a Taxable Equivalent Basis
  Three Months Ended,
  September 30, 2026   June 30, 2026   September 30, 2025
  Average
Balance
  Annual
Rate
  Interest
Inc./Exp.
  Average
Balance
  Annual
Rate
  Interest
Inc./Exp.
  Average
Balance
  Annual
Rate
  Interest
Inc./Exp.
ASSETS:                                  
Securities:                                  
Taxable (1) (4) $ 867,953     3.26 %   $ 7,503   $ 881,420     3.26 %   $ 7,489   $ 797,866     2.92 %   $ 6,151
Tax-exempt (1) (2) (4)   21,715     2.77       163     22,677     2.81       169     24,531     2.62       174
Equity securities (1) (2)   36,488     7.89       726     36,853     9.16       842     21,044     1.79       95
Total securities (4)   926,156     3.42       8,392     940,950     3.47       8,500     843,441     2.89       6,420
Loans receivable:                                  
Commercial (2) (3)   1,916,991     6.54       31,593     1,837,643     6.84       31,358     1,644,092     6.98       28,921
Commercial & residential mortgages and loans held for sale (2) (3)   4,511,322     6.09       69,230     4,489,655     6.07       67,922     4,212,211     6.19       65,752
Consumer (3)   135,790     10.23       3,500     134,358     10.31       3,452     127,428     11.52       3,701
Total loans receivable (3)   6,564,103     6.31       104,323     6,461,656     6.38       102,732     5,983,731     6.52       98,374
Interest-bearing deposits with the Federal Reserve and other financial institutions   295,545     3.70       2,756     480,454     4.11       4,921     394,484     4.19       4,165
Total earning assets   7,785,804     5.85     $ 115,471     7,883,060     5.88     $ 116,153     7,221,656     5.96     $ 108,959
Noninterest-bearing assets:                                  
Cash and due from banks   76,192               74,387               77,224          
Premises and equipment   144,600               145,813               145,087          
Other assets   448,828               439,235               416,992          
Allowance for credit losses   (67,722 )             (67,119 )             (62,092 )        
Total non interest-bearing assets   601,898               592,316               577,211          
TOTAL ASSETS $ 8,387,702             $ 8,475,376             $ 7,798,867          
LIABILITIES AND SHAREHOLDERS’ EQUITY:                                  
Demand—interest-bearing $ 1,043,288     0.96 %   $ 2,517   $ 1,046,730     0.92 %   $ 2,406   $ 913,337     1.00 %   $ 2,291
Savings   3,748,029     2.47       23,361     3,815,404     2.50       23,774     3,501,326     2.86       25,200
Time   1,149,064     3.48       10,067     1,169,220     3.52       10,274     1,062,394     3.90       10,450
Total interest-bearing deposits   5,940,381     2.40       35,945     6,031,354     2.42       36,454     5,477,057     2.75       37,941
Short-term borrowings   164,000     4.03       1,664     164,000     3.96       1,619     218,871     4.08       2,251
Finance lease liabilities   17,995     5.31       241     18,014     5.30       238     18,079     5.49       250
Subordinated notes and debentures   55,620     6.01       842     96,435     4.16       1,001     105,380     4.04       1,074
Total interest-bearing liabilities   6,177,996     2.48     $ 38,692     6,309,803     2.50     $ 39,312     5,819,387     2.83     $ 41,516
Demand—noninterest-bearing   1,169,691               1,153,386               1,078,091          
Other liabilities   119,305               114,894               112,123          
Total Liabilities   7,466,992               7,578,083               7,009,601          
Shareholders’ equity   920,710               897,293               789,266          
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 8,387,702             $ 8,475,376             $ 7,798,867          
Interest income/Earning assets     5.85 %   $ 115,471       5.88 %   $ 116,153       5.96 %   $ 108,959
Interest expense/Interest-bearing liabilities     2.48       38,692       2.50       39,312       2.83       41,516
Net interest spread     3.37 %   $ 76,779       3.38 %   $ 76,841       3.13 %   $ 67,443
Interest income/Earning assets     5.85 %     115,471       5.88 %     116,153       5.96 %     108,959
Interest expense/Earning assets     1.96       38,692       1.99       39,312       2.27       41,516
Net interest margin (fully tax-equivalent)     3.89 %   $ 76,779       3.89 %   $ 76,841       3.69 %   $ 67,443
                                               
(1) Includes unamortized discounts and premiums.
(2) Average yields are stated on a fully taxable equivalent basis (calculated using statutory rates of 21%) resulting from tax-free municipal securities in the investment portfolio and tax-free municipal loans in the commercial loan portfolio. The taxable equivalent adjustment to net interest income for the three months ended September 30, 2026, June 30, 2026, and September 30, 2025 was $474 thousand, $497 thousand and $314 thousand, respectively.
(3) Average loans receivable outstanding includes the average balance outstanding of all nonaccrual loans. Loans receivable consists of the average of total loans receivable less average unearned income. In addition, loans receivable interest income consists of loans receivable fees.
(4) Average balance is computed using the fair value of AFS securities and amortized cost of HTM securities. Average yield has been computed using amortized cost average balance for AFS and HTM securities. The adjustment to the average balance for securities in the calculation of average yield for the three months ended September 30, 2026, June 30, 2026, and September 30, 2025 was $(47.1) million, $(40.2) million and $(39.1) million, respectively.
 

 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
   
  Average Balances, Income and Interest Rates on a Taxable Equivalent Basis
  Nine Months Ended,
  September 30, 2026   September 30, 2025
  Average
Balance
  Annual
Rate
  Interest
Inc./Exp.
  Average
Balance
  Annual
Rate
  Interest
Inc./Exp.
ASSETS:                      
Securities:                      
Taxable (1) (4) $ 872,844     3.22 %   $ 21,932   $ 778,262     2.82 %   $ 17,308
Tax-exempt (1) (2) (4)   22,791     2.80       507     24,709     2.64       528
Equity securities (1) (2)   34,259     7.89       2,023     12,079     3.38       305
Total securities (4)   929,894     3.37       24,462     815,050     2.83       18,141
Loans receivable:                      
Commercial (2) (3)   1,838,301     6.71       92,250     1,528,643     6.82       77,954
Commercial & residential mortgages and loans held for sale (2) (3)   4,528,930     6.08       206,059     3,431,785     6.14       157,620
Consumer (3)   134,351     10.35       10,403     125,776     11.74       11,047
Total loans receivable (3)   6,501,582     6.35       308,712     5,086,204     6.48       246,621
Interest-bearing deposits with the Federal Reserve and other financial institutions   378,825     3.84       10,883     384,762     4.47       12,871
Total earning assets   7,810,301     5.86     $ 344,057     6,286,016     5.87     $ 277,633
Noninterest-bearing assets:                      
Cash and due from banks   76,341               64,701          
Premises and equipment   146,107               134,523          
Other assets   444,370               324,414          
Allowance for credit losses   (67,292 )             (52,181 )        
Total non interest-bearing assets   599,526               471,457          
TOTAL ASSETS $ 8,409,827             $ 6,757,473          
LIABILITIES AND SHAREHOLDERS’ EQUITY:                      
Demand—interest-bearing $ 1,035,317     0.94 %   $ 7,254   $ 776,145     0.95 %   $ 5,537
Savings   3,794,154     2.50       70,898     3,248,202     2.98       72,326
Time   1,142,899     3.53       30,214     849,122     3.93       24,988
Total interest-bearing deposits   5,972,370     2.43       108,366     4,873,469     2.82       102,851
Short-term borrowings   164,000     3.87       4,749     73,785     4.08       2,251
Finance lease liabilities   18,016     5.31       715     16,704     5.67       708
Subordinated notes and debentures   86,916     4.44       2,889     105,304     4.10       3,228
Total interest-bearing liabilities   6,241,302     2.50     $ 116,719     5,069,262     2.88     $ 109,038
Demand—noninterest-bearing   1,149,662               909,597          
Other liabilities   118,363               98,414          
Total Liabilities   7,509,327               6,077,273          
Shareholders’ equity   900,500               680,200          
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY $ 8,409,827             $ 6,757,473          
Interest income/Earning assets     5.86 %   $ 344,057       5.87 %   $ 277,633
Interest expense/Interest-bearing liabilities     2.50       116,719       2.88       109,038
Net interest spread     3.36 %   $ 227,338       2.99 %   $ 168,595
Interest income/Earning assets     5.86 %     344,057       5.87 %     277,633
Interest expense/Earning assets     1.99       116,719       2.31       109,038
Net interest margin (fully tax-equivalent)     3.87 %   $ 227,338       3.56 %   $ 168,595
                               
(1) Includes unamortized discounts and premiums.
(2) Average yields are stated on a fully taxable equivalent basis (calculated using statutory rates of 21%) resulting from tax-free municipal securities in the investment portfolio and tax-free municipal loans in the commercial loan portfolio. The taxable equivalent adjustment to net interest income for the nine months ended September 30, 2026 and 2025, was $1.4 million and $838 thousand, respectively.
(3) Average loans receivable outstanding includes the average balance outstanding of all nonaccrual loans. Loans receivable consist of the average of total loans receivable less average unearned income. In addition, loans receivable interest income consists of loans receivable fees, including PPP deferred processing fees.
(4) Average balance is computed using the fair value of AFS securities and amortized cost of HTM securities. Average yield has been computed using amortized cost average balance for AFS and HTM securities. The adjustment to the average balance for securities in the calculation of average yield for the nine months ended September 30, 2026 and 2025 was $(39.9) million and $(43.2) million, respectively.
 

 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
 
Reconciliation of Non-GAAP Financial Measures
       
  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Calculation of merger transaction related expenses, net of tax (non-GAAP) (1):                  
Merger and integration costs – non deductible $ —     $ —     $ 1,570     $ —     $ 2,897  
                   
Merger and integration costs – deductible   —       —       2,586       —       3,144  
Statutory federal tax rate   21 %     21 %     21 %     21 %     21 %
Tax benefit of merger and integration costs (non-GAAP)   —       —       543       —       660  
Merger transaction related expenses – deductible, net of tax   —       —       2,043       —       2,484  
                   
Merger transaction related expenses, net of tax (non-GAAP) $ —     $ —     $ 3,613     $ —     $ 5,381  
                   
(1) Merger transaction related expenses represent legal, advisory, severance, technology conversion, and other expenses directly related to the ESSA acquisition. Management believes exclusion of these non-recurring charges provides more meaningful period-over-period comparisons of operating performance.

  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Calculation of net income available to common (GAAP):                  
Net income $ 28,061   $ 28,304   $ 19,990   $ 83,401   $ 45,427
Less: preferred stock dividends   1,076     1,075     1,076     3,226     3,226
Net income available to common shareholders $ 26,985   $ 27,229   $ 18,914   $ 80,175   $ 42,201
                   
Adjusted calculation of net income available to common (non-GAAP):                  
Net income available to common shareholders $ 26,985   $ 27,229   $ 18,914   $ 80,175   $ 42,201
Add: merger transaction related expenses, net of tax (non-GAAP)   —     —     3,613     —     5,381
Adjusted net income available to common shareholders (non-GAAP) $ 26,985   $ 27,229   $ 22,527   $ 80,175   $ 47,582

  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Calculation of dividend payout ratio:                  
Cash dividends per common share $ 0.19     $ 0.19     $ 0.18     $ 0.57     $ 0.54  
Diluted earnings per common share   0.91       0.91       0.69       2.69       1.81  
Dividend payout ratio   21 %     21 %     26 %     21 %     30 %
                   
Adjusted calculation of dividend payout ratio (non-GAAP):                  
Cash dividends per common share $ 0.19     $ 0.19     $ 0.18     $ 0.57     $ 0.54  
Adjusted diluted earnings per common share (non-GAAP)   0.91       0.91       0.82       2.69       2.05  
Adjusted dividend payout ratio (non-GAAP)   21 %     21 %     22 %     21 %     26 %

  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Calculation of PPNR (non-GAAP): (1)                  
Net interest income $ 76,305   $ 76,344   $ 67,129   $ 225,972   $ 167,757
Add: Non-interest income   11,489     11,302     10,566     32,789     28,081
Less: Non-interest expense   51,104     50,708     50,157     150,999     130,812
PPNR (non-GAAP) $ 36,690   $ 36,938   $ 27,538   $ 107,762   $ 65,026
                   
Adjusted calculation of PPNR (non-GAAP): (1)                  
Net interest income $ 76,305   $ 76,344   $ 67,129   $ 225,972   $ 167,757
Add: Non-interest income   11,489     11,302     10,566     32,789     28,081
Less: Non-interest expense   51,104     50,708     50,157     150,999     130,812
Add: Merger and integration costs (non-GAAP)   —     —     4,155     —     6,041
Adjusted PPNR (non-GAAP) $ 36,690   $ 36,938   $ 31,693   $ 107,762   $ 71,067
                   
(1) Management believes that this is an important metric as it illustrates the underlying performance of the Corporation, it enables investors and others to assess the Corporation’s ability to generate capital to cover credit losses through the credit cycle and provides consistent reporting with a key metric used by bank regulatory agencies.

  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Calculation of net interest margin:                  
Interest income $ 114,997     $ 115,656     $ 108,645     $ 342,691     $ 276,795  
Interest expense   38,692       39,312       41,516       116,719       109,038  
Net interest income $ 76,305     $ 76,344     $ 67,129     $ 225,972     $ 167,757  
                   
Average total earning assets $ 7,785,804     $ 7,883,060     $ 7,221,656     $ 7,810,301     $ 6,286,016  
                   
Net interest margin (GAAP) (annualized)   3.89 %     3.88 %     3.69 %     3.87 %     3.57 %
                   
Calculation of net interest margin (fully tax equivalent basis) (non-GAAP):                  
Interest income $ 114,997     $ 115,656     $ 108,645     $ 342,691     $ 276,795  
Tax equivalent adjustment (non-GAAP)   474       497       314       1,366       838  
Adjusted interest income (fully tax equivalent basis) (non-GAAP)   115,471       116,153       108,959       344,057       277,633  
Interest expense   38,692       39,312       41,516       116,719       109,038  
Net interest income (fully tax equivalent basis) (non-GAAP) $ 76,779     $ 76,841     $ 67,443     $ 227,338     $ 168,595  
                   
Average total earning assets $ 7,785,804     $ 7,883,060     $ 7,221,656     $ 7,810,301     $ 6,286,016  
Less: average mark to market adjustment on investments (non-GAAP)   (47,088 )     (40,194 )     (39,121 )     (39,872 )     (43,229 )
Adjusted average total earning assets, net of mark to market (non-GAAP) $ 7,832,892     $ 7,923,254     $ 7,260,777     $ 7,850,173     $ 6,329,245  
                   
Net interest margin, fully tax equivalent basis (non-GAAP) (annualized)   3.89 %     3.89 %     3.69 %     3.87 %     3.56 %
                   
Calculation of net interest margin, excluding purchase accounting loan accretion (fully tax equivalent basis) (non-GAAP) (1):                  
Net interest income (fully tax equivalent basis) (non-GAAP) $ 76,779     $ 76,841     $ 67,443     $ 227,338     $ 168,595  
Less: purchase accounting loan accretion   (2,738 )     (4,785 )     (3,420 )     (10,563 )     (3,420 )
Adjusted net interest income (fully tax equivalent basis) (non-GAAP) $ 74,041     $ 72,056     $ 64,023     $ 216,775       165,175  
                   
Adjusted average total earning assets, net of mark to market (non-GAAP) $ 7,832,892     $ 7,923,254     $ 7,260,777     $ 7,850,173     $ 6,329,245  
Adjusted net interest margin, fully tax equivalent basis (non-GAAP) (annualized)   3.75 %     3.65 %     3.50 %     3.69 %     3.49 %
(1) Purchase accounting loan accretion represents income recognized on estimated fair value adjustments to acquired loans.
 


 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
 
Reconciliation of Non-GAAP Financial Measures
       
  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Basic earnings per common share computation:                  
Net income available to common shareholders $ 26,985   $ 27,229   $ 18,914   $ 80,175   $ 42,201
Less: net income available to common shareholders allocated to participating securities   225     256     149     715     345
Net income available to common shareholders allocated to common stock $ 26,760   $ 26,973   $ 18,765   $ 79,460   $ 41,856
                   
Weighted average common shares outstanding, including shares considered participating securities   29,621     29,627     27,388     29,608     23,165
Less: average participating securities   233     273     209     255     166
Weighted average shares   29,388     29,354     27,179     29,353     22,999
Basic earnings per common share $ 0.91   $ 0.92   $ 0.69   $ 2.71   $ 1.82
                   
Diluted earnings per common share computation:                  
Net income available to common shareholders allocated to common stock $ 26,760   $ 26,973   $ 18,765   $ 79,460   $ 41,856
                   
Weighted average common shares outstanding for basic earnings per common share   29,388     29,354     27,179     29,353     22,999
Add: dilutive effect of stock compensation   145     138     101     137     76
Weighted average shares and dilutive potential common shares   29,533     29,492     27,280     29,490     23,075
Diluted earnings per common share $ 0.91   $ 0.91   $ 0.69   $ 2.69   $ 1.81
                   
Adjusted basic earnings per common share computation (non-GAAP):                  
Net income available to common shareholders $ 26,985   $ 27,229   $ 18,914   $ 80,175   $ 42,201
Add: merger transaction related expenses, net of tax (non-GAAP)   —     —     3,613     —     5,381
Less: net income available to common shareholders allocated to participating securities   225     256     149     715     345
Adjustment to net income available to common shareholders allocated to participating securities for merger transaction related expenses, net of tax (non-GAAP)   —     —     28     —     39
Adjusted net income available to common shareholders allocated to common stock (non-GAAP) $ 26,760   $ 26,973   $ 22,350   $ 79,460   $ 47,198
                   
Weighted average common shares outstanding, including shares considered participating securities   29,621     29,627     27,388     29,608     23,165
Less: average participating securities   233     273     209     255     166
Weighted average shares   29,388     29,354     27,179     29,353     22,999
Adjusted basic earnings per common share (non-GAAP) $ 0.91   $ 0.92   $ 0.82   $ 2.71   $ 2.05
                   
Adjusted diluted earnings per common share computation (non-GAAP):                  
Adjusted net income available to common shareholders allocated to common stock (non-GAAP) $ 26,760   $ 26,973   $ 22,350   $ 79,460   $ 47,198
                   
Weighted average common shares outstanding for basic earnings per common share   29,388     29,354     27,179     29,353     22,999
Add: dilutive effect of stock compensation   145     138     101     137     76
Weighted average shares and dilutive potential common shares   29,533     29,492     27,280     29,490     23,075
Adjusted diluted earnings per common share (non-GAAP) $ 0.91   $ 0.91   $ 0.82   $ 2.69   $ 2.05
                             


 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
 
Reconciliation of Non-GAAP Financial Measures
           
  September 30,
2026
  June 30,
2026
  September 30,
2025
Calculation of tangible book value per common share and tangible common
equity / tangible assets (non-GAAP):
         
Shareholders’ equity $ 912,550     $ 909,447     $ 857,130  
Less: preferred equity   57,785       57,785       57,785  
Common shareholders’ equity   854,765       851,662       799,345  
Less: goodwill and other intangibles   87,465       87,465       93,773  
Less: core deposit intangible   30,646       31,672       34,727  
Tangible common equity (non-GAAP) $ 736,654     $ 732,525     $ 670,845  
           
Total assets $ 8,385,117     $ 8,432,169     $ 8,270,706  
Less: goodwill and other intangibles   87,465       87,465       93,773  
Less: core deposit intangible   30,646       31,672       34,727  
Tangible assets (non-GAAP) $ 8,267,006     $ 8,313,032     $ 8,142,206  
           
Ending shares outstanding   29,620,028       29,621,999       29,477,429  
           
Book value per common share (GAAP) $ 28.86     $ 28.75     $ 27.12  
Tangible book value per common share (non-GAAP) $ 24.87     $ 24.73     $ 22.76  
           
Common shareholders’ equity / Total assets (GAAP)   10.19 %     10.10 %     9.66 %
Tangible common equity / Tangible assets (non-GAAP)   8.91 %     8.81 %     8.24 %
           
Adjusted calculation of book value per common share (non-GAAP):          
Common shareholders’ equity $ 854,765     $ 851,662     $ 799,345  
Add: merger transaction related expenses, net of tax (non-GAAP)   —       —       5,381  
Adjusted common shareholders’ equity (non-GAAP) $ 854,765     $ 851,662     $ 804,726  
           
Ending shares outstanding   29,620,028       29,621,999       29,477,429  
           
Adjusted book value per common share (non-GAAP) $ 28.86     $ 28.75     $ 27.30  
           
Adjusted calculation of tangible book value per common share (non-GAAP):          
Tangible common equity (non-GAAP) $ 736,654     $ 732,525     $ 670,845  
Add: merger transaction related expenses, net of tax (non-GAAP)   —       —       5,381  
Adjusted tangible common equity (non-GAAP) $ 736,654     $ 732,525     $ 676,226  
           
Ending shares outstanding   29,620,028       29,621,999       29,477,429  
           
Adjusted tangible book value per common share (non-GAAP) $ 24.87     $ 24.73     $ 22.94  
           
Adjusted calculation of tangible common equity / tangible assets (non-GAAP):          
Adjusted tangible common shareholders’ equity (non-GAAP) $ 736,654     $ 732,525     $ 676,226  
           
Tangible assets (non-GAAP) $ 8,267,006     $ 8,313,032     $ 8,142,206  
Add: merger and integration costs (non-GAAP)   —       —       6,041  
Adjusted tangible assets (non-GAAP) $ 8,267,006     $ 8,313,032     $ 8,148,247  
           
Adjusted tangible common equity / Adjusted tangible assets (non-GAAP)   8.91 %     8.81 %     8.30 %
                       


 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
 
Reconciliation of Non-GAAP Financial Measures
       
  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Calculation of efficiency ratio:                  
Non-interest expense $ 51,104     $ 50,708     $ 50,157     $ 150,999     $ 130,812  
                   
Non-interest income $ 11,489     $ 11,302     $ 10,566     $ 32,789     $ 28,081  
Net interest income   76,305       76,344       67,129       225,972       167,757  
Total revenue $ 87,794     $ 87,646     $ 77,695     $ 258,761     $ 195,838  
Efficiency ratio   58.21 %     57.86 %     64.56 %     58.35 %     66.80 %
                   
Calculation of efficiency ratio (fully tax equivalent basis) (non-GAAP):                  
Non-interest expense $ 51,104     $ 50,708     $ 50,157     $ 150,999     $ 130,812  
Less: core deposit intangible amortization   1,025       1,016       780       3,046       813  
Adjusted non-interest expense (non-GAAP) $ 50,079     $ 49,692     $ 49,377     $ 147,953     $ 129,999  
                   
Non-interest income $ 11,489     $ 11,302     $ 10,566     $ 32,789     $ 28,081  
                   
Net interest income $ 76,305     $ 76,344     $ 67,129     $ 225,972     $ 167,757  
Less: tax exempt investment and loan income, net of TEFRA (non-GAAP)   2,217       2,391       1,737       6,573       4,652  
Add: tax exempt investment and loan income (fully tax equivalent basis) (non-GAAP)   3,010       3,265       2,453       8,978       6,575  
Adjusted net interest income (fully tax equivalent basis) (non-GAAP)   77,098       77,218       67,845       228,377       169,680  
Adjusted net revenue (fully tax equivalent basis) (non-GAAP) $ 88,587     $ 88,520     $ 78,411     $ 261,166     $ 197,761  
                   
Efficiency ratio (fully tax equivalent basis) (non-GAAP)   56.53 %     56.14 %     62.97 %     56.65 %     65.74 %
                   
Adjusted calculation of efficiency ratio (fully tax equivalent basis) (non-GAAP):                  
Adjusted non-interest expense (non-GAAP) $ 50,079     $ 49,692     $ 49,377     $ 147,953     $ 129,999  
Less: merger and integration costs (non-GAAP)   —       —       4,155       —       6,041  
Adjusted non-interest expense (non-GAAP) $ 50,079     $ 49,692     $ 45,222     $ 147,953     $ 123,958  
                   
Adjusted net revenue (fully tax equivalent basis) (non-GAAP) $ 88,587     $ 88,520     $ 78,411     $ 261,166     $ 197,761  
                   
Adjusted efficiency ratio (fully tax equivalent basis) (non-GAAP)   56.53 %     56.14 %     57.67 %     56.65 %     62.68 %
                                       


 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
 
Reconciliation of Non-GAAP Financial Measures
       
  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Calculation of return on average tangible common equity (non-GAAP):                  
Net income $ 28,061     $ 28,304     $ 19,990     $ 83,401     $ 45,427  
Less: preferred stock dividends   1,076       1,075       1,076       3,226       3,226  
Net income available to common shareholders $ 26,985     $ 27,229     $ 18,914     $ 80,175     $ 42,201  
                   
Average shareholders’ equity $ 920,710     $ 897,293     $ 789,266     $ 900,500     $ 680,200  
Less: average goodwill & intangibles   118,783       120,838       107,827       120,482       65,554  
Less: average preferred equity   57,785       57,785       57,785       57,785       57,785  
Average tangible common shareholders’ equity (non-GAAP) $ 744,142     $ 718,670     $ 623,654     $ 722,233     $ 556,861  
                   
Return on average equity (GAAP) (annualized)   12.09 %     12.65 %     10.05 %     12.38 %     8.93 %
Return on average common equity (GAAP) (annualized)   12.41 %     13.01 %     10.26 %     12.72 %     9.07 %
Return on average tangible common equity (non-GAAP) (annualized)   14.39 %     15.20 %     12.03 %     14.84 %     10.13 %
                   
Adjusted calculation of return on average equity (non-GAAP):                  
Net income $ 28,061     $ 28,304     $ 19,990     $ 83,401     $ 45,427  
Add: merger transaction related expenses, net of tax (non-GAAP)   —       —       3,613       —       5,381  
Adjusted net income (non-GAAP) $ 28,061     $ 28,304     $ 23,603     $ 83,401     $ 50,808  
                   
Average shareholders’ equity $ 920,710     $ 897,293     $ 789,266     $ 900,500     $ 680,200  
                   
Adjusted return on average equity (non-GAAP) (annualized)   12.09 %     12.65 %     11.86 %     12.38 %     9.99 %
                   
Adjusted calculation of return on average tangible common equity (non-GAAP):                  
Net income available to common shareholders $ 26,985     $ 27,229     $ 18,914     $ 80,175     $ 42,201  
Add: merger transaction related expenses, net of tax (non-GAAP)   —       —       3,613       —       5,381  
Adjusted net income available to common shareholders $ 26,985     $ 27,229     $ 22,527     $ 80,175     $ 47,582  
                   
Average tangible common shareholders’ equity (non-GAAP) $ 744,142     $ 718,670     $ 623,654     $ 722,233     $ 556,861  
                   
Adjusted return on average tangible common equity (non-GAAP) (annualized)   14.39 %     15.20 %     14.33 %     14.84 %     11.42 %
                                       


 
CNB FINANCIAL CORPORATION
CONSOLIDATED FINANCIAL DATA
Unaudited
(dollars in thousands, except per share data)
 
Reconciliation of Non-GAAP Financial Measures
       
  Three Months Ended   Nine Months Ended
  September 30,
2026
  June 30,
2026
  September 30,
2025
  September 30,
2026
  September 30,
2025
Calculation of return on average assets:                  
Net income $ 28,061     $ 28,304     $ 19,990     $ 83,401     $ 45,427  
Average total assets $ 8,387,702     $ 8,475,376     $ 7,798,867     $ 8,409,827     $ 6,757,473  
                   
Return on average assets (GAAP) (annualized)   1.33 %     1.34 %     1.02 %     1.33 %     0.90 %
                   
Adjusted calculation of return on average assets (non-GAAP):                  
Net income $ 28,061     $ 28,304     $ 19,990     $ 83,401     $ 45,427  
Add: merger transaction related expenses, net of tax (non-GAAP)   —       —       3,613       —       5,381  
Adjusted net income $ 28,061     $ 28,304     $ 23,603     $ 83,401     $ 50,808  
Average total assets $ 8,387,702     $ 8,475,376     $ 7,798,867     $ 8,409,827     $ 6,757,473  
                   
Adjusted return on average assets (non-GAAP) (annualized)   1.33 %     1.34 %     1.20 %     1.33 %     1.01 %
                                       

CONTACT: Contact: Tito L. Lima
Treasurer
(814) 765-9621

  • Record quarterly revenue of $4.02 billion, up 12% year-over-year; diluted EPS of $0.57, up 54%
  • Operating income of $1.57 billion, up 44%; operating margin expanded 880 bps to 39.1%
  • Total volume up 5%, with intermodal volume increasing by 7%

JACKSONVILLE, Fla., Oct. 21, 2026 (GLOBE NEWSWIRE) — CSX Corp. (NASDAQ: CSX) today announced third quarter 2026 operating income of $1.57 billion and net earnings of $1.05 billion, or $0.57 per diluted share. In the third quarter of 2025, the company reported operating income of $1.09 billion and net earnings of $694 million, or $0.37 per diluted share. Excluding a non-cash goodwill impairment of $164 million in last year’s results, third quarter 2025 adjusted operating income, net earnings, and EPS were $1.25 billion, $818 million, and $0.44, respectively. On a year-over-year basis and compared to adjusted results, operating income increased 25%, net earnings increased 29%, and EPS increased 30%.

Total volume of 1.69 million units for the quarter was 5% higher than third quarter 2025. Revenue totaled $4.02 billion for the quarter, increasing 12% year-over-year, due to increased fuel surcharge revenue together with higher volume and pricing across merchandise, intermodal, and coal.

“CSX delivered strong earnings growth in the third quarter as disciplined execution helped us move more freight, for more customers, while maintaining our high standards for safety and service,” said Steve Angel, president and chief executive officer. “The hard work of our railroaders has positioned us well as we enter the fourth quarter, and we look forward to making continued progress toward best-in-class performance in 2027.”

CSX executives will conduct a conference call with the investment community this afternoon, October 21, at 4:30 p.m. Eastern Time. Investors, media, and the public may listen to the conference call by dialing 1-888-510-2008. For callers outside the U.S., dial 1-646-960-0306. Participants should dial in 10 minutes prior to the call and enter 3368220 as the passcode.

In conjunction with the call, a live webcast will be accessible and presentation materials will be posted on the company’s website at investors.csx.com. Following the earnings call, a webcast replay of the presentation will be archived on the company’s website.

This earnings announcement, as well as additional detailed financial information, is contained in the CSX Quarterly Financial Report available through the company’s website at investors.csx.com and on Form 8-K with the Securities and Exchange Commission.

About CSX and its Disclosures

CSX, based in Jacksonville, Florida, is a premier transportation company. It provides rail, intermodal and rail-to-truck transload services and solutions to customers across a broad array of markets, including energy, industrial, construction, agricultural, and consumer products. For nearly 200 years, CSX has played a critical role in the nation’s economic expansion and industrial development. Its network connects every major metropolitan area in the eastern United States, where nearly two-thirds of the nation’s population resides. It also links approximately 250 short-line railroads and more than 70 ocean, river and lake ports with major population centers and farming towns alike.

This announcement, as well as additional financial information, is available on the company’s website at investors.csx.com. CSX also uses social media channels to communicate information about the company. Although social media channels are not intended to be the primary method of disclosure for material information, it is possible that certain information CSX posts on social media could be deemed to be material. Therefore, we encourage investors, the media, and others interested in the company to review the information we post on X (x.com/CSX) and on Facebook (facebook.com/OfficialCSX). The social media channels used by CSX may be updated from time to time. More information about CSX Corporation and its subsidiaries is available at www.csx.com.

Non-GAAP Disclosure

CSX reports its financial results in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). CSX also uses certain non-GAAP measures that fall within the meaning of Securities and Exchange Commission Regulation G and Regulation S-K Item 10(e), which may provide users of the financial information with additional meaningful comparisons to prior reported results. Non-GAAP measures do not have standardized definitions and are not defined by U.S. GAAP. Therefore, CSX’s non-GAAP measures are unlikely to be comparable to similar measures presented by other companies. The presentation of these non-GAAP measures should not be considered in isolation from, as a substitute for, or as superior to the financial information presented in accordance with GAAP.

Forward-looking Statements

This information and other statements by the company may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to, among other items: projections and estimates of earnings, revenues, margins, volumes, rates, cost-savings, expenses, taxes, liquidity, capital expenditures, dividends, share repurchases or other financial items, statements of management’s plans, strategies and objectives for future operations, and management’s expectations as to future performance and operations and the time by which objectives will be achieved, statements concerning proposed new services, and statements regarding future economic, industry or market conditions or performance. Forward-looking statements are typically identified by words or phrases such as “will,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “preliminary” and similar expressions. Forward-looking statements speak only as of the date they are made, and the company undertakes no obligation to update or revise any forward-looking statement. If the company updates any forward-looking statement, no inference should be drawn that the company will make additional updates with respect to that statement or any other forward-looking statements.

Forward-looking statements are subject to a number of risks and uncertainties, and actual performance or results could differ materially from that anticipated by any forward-looking statements. Factors that may cause actual results to differ materially from those contemplated by any forward-looking statements include, among others: (i) the company’s success in implementing its financial and operational initiatives; (ii) changes in domestic or international economic, political or business conditions, including those affecting the transportation industry (such as the impact of industry competition, conditions, performance and consolidation); (iii) legislative or regulatory changes; (iv) the inherent business risks associated with safety and security; (v) the outcome of claims and litigation involving or affecting the company; (vi) natural events such as severe weather conditions or pandemic health crises; (vii) changes in fuel prices, surcharges for fuel and the availability of fuel; (viii) adverse economic or operational effects from actual or threatened war or terrorist activities and any government response; and (ix) the inherent uncertainty associated with projecting economic and business conditions.

Other important assumptions and factors that could cause actual results to differ materially from those in the forward-looking statements are specified in the company’s SEC reports, accessible on the SEC’s website at www.sec.gov and the company’s website at www.csx.com.

Contact:

Matthew Korn, CFA, Investor Relations
904-366-4515

Austin Staton, Corporate Communications
855-955-6397

MILAN, Italy, Oct. 21, 2026 (GLOBE NEWSWIRE) — Genenta Science S.p.A. (Nasdaq: GNTA) (the “Company”) today announced that on October 16, 2026, it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the minimum bid price requirement of $1.00 per share under Nasdaq Listing Rule 5550(a)(2).

The notification was issued because the closing bid price of the Company’s American Depositary Shares (“ADSs”) was below $1.00 per ADS for 30 consecutive business days, from September 3, 2026 through October 15, 2026. The notification does not result in the immediate delisting of the Company’s ADSs, which will continue to trade on the Nasdaq Capital Market under the symbol “GNTA,” subject to the Company’s continued compliance with other applicable listing requirements.

Under Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, until April 14, 2027, to regain compliance with the minimum bid price requirement. To regain compliance, the closing bid price of the Company’s ADSs must be at least $1.00 per ADS for a minimum of 10 consecutive business days during the compliance period, unless Nasdaq exercises its discretion to extend this period.

If the Company does not regain compliance by April 14, 2027, it may be eligible for an additional 180-calendar-day compliance period, provided that it satisfies the applicable market value of publicly held shares requirement and all other initial listing standards for the Nasdaq Capital Market, except the minimum bid price requirement, and provides written notice of its intention to cure the deficiency, including by effecting a reverse stock split, if necessary.

As previously disclosed, the Company’s shareholders have already approved a reverse stock split within a range of 1-for-10 to 1-for-20, which the Board of Directors is authorized to implement, if deemed appropriate.

The Company intends to monitor the closing bid price of its ADSs and evaluate available options to regain compliance with Nasdaq’s minimum bid price requirement. Although the Company will use all reasonable efforts, there can be no assurance that it will regain compliance within the initial compliance period, qualify for any additional compliance period, or otherwise remain in compliance with other Nasdaq continued listing requirements.

About Genenta Science

Genenta Science (Nasdaq: GNTA) is evolving into a next-generation strategic consolidator focused on privately held specialized companies operating in Italian national security-regulated sectors, with activities spanning cybersecurity, defense, aerospace, and biotechnology/biosecurity. Genenta holds a 19% equity interest in Sòphia High Tech and has an option to increase its ownership to 51% at a pre-agreed valuation.

Forward-Looking Statements

This press release contains forward-looking statements, including statements regarding the Company’s intentions and ability to regain compliance with Nasdaq’s minimum bid price requirement and maintain its Nasdaq listing. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including fluctuations in the market price of the Company’s ADSs and the Company’s ability to satisfy Nasdaq’s continued listing requirements. Additional risks and uncertainties are described in the Company’s filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update these statements except as required by applicable law.

CONTACT: Investor Relations

Genenta Science S.p.A.
Tiziana Pollio, Mobile: +39 348 23 15 143
email: tiziana.pollio@genenta.com

RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2026 (GLOBE NEWSWIRE) — BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its third quarter 2026 financial results on Wednesday, November 4, 2026.

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

A live webcast and replay of the call will be available online in the investors section of the company website at www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst is a global biotechnology company focused on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases, driven by its deep commitment to improving the lives of people living with these conditions. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor and is advancing a pipeline of potential first-in-class or best-in-class therapeutics for rare diseases. For more information, please visit www.biocryst.com or follow us on LinkedIn.

BCRXW

Contact:

Investors:
investorrelations@biocryst.com

Media:
media@biocryst.com

WESTLAKE VILLAGE, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that it will report its third quarter 2026 financial results and provide a business update after the U.S. financial markets close on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 4:30 p.m. ET that same day.

A live webcast of the call and related presentation materials will be available on the “Events” section of the Company’s website. A replay of the webcast will be available on the Arcutis investor website following the conference call.

About Arcutis
Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company delivering meaningful innovation to address the needs of individuals living with chronic inflammatory skin diseases. Over the past decade, Arcutis has successfully developed a robust portfolio of advanced targeted topicals approved to treat three major inflammatory skin diseases, driven by a commitment to solving the most persistent patient challenges in dermatology. Arcutis’ unique dermatology development platform, built on established scientific pathways and coupled with deep clinical dermatology and commercial expertise, enables us to efficiently develop, scale, and deliver our differentiated therapies while advancing a growing pipeline across a range of inflammatory dermatological conditions. For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X. 

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. For example, statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the Company’s current beliefs and expectations. These statements are subject to substantial known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from the information expressed or implied by these forward-looking statements. Risks and uncertainties that may cause our actual results to differ include risks inherent in our business, reimbursement and access to our products, the impact of competition and other important factors discussed in the “Risk Factors” section of our Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on February 25, 2026, as well as any subsequent filings with the SEC. Any forward-looking statements that the Company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as amended, and speak only as of the date of this press release. Except as required by law, we undertake no obligation to revise or update information herein to reflect events or circumstances in the future, even if new information becomes available..

Contacts:
Media
Amanda Sheldon, Head of Corporate Communications
media@arcutis.com

Investors
Brian Schoelkopf, Head of Investor Relations
ir@arcutis.com

NEW YORK, Oct. 21, 2026 (GLOBE NEWSWIRE) — National Healthcare Properties, Inc. (Nasdaq: NHP) (“NHP”) announced today that Lindsay Gordon, Executive Vice President and Head of Senior Housing, has been elected to the executive board of the American Senior Housing Association (ASHA).

ASHA is the premier national organization representing owners, operators, developers and investors in the seniors housing industry. ASHA advocates on federal policy, produces industry-defining research and provides thought leadership on issues shaping independent living, assisted living, memory care and life plan communities. ASHA is the nation’s premier organization for executives in the senior living industry.

Ms. Gordon leads a dedicated senior housing asset management team at NHP with significant experience in senior housing operations, supporting robust partnerships with leading national operators. She has over 30 years of experience in senior housing across community, regional and corporate roles with a focus on sales and operations. Her prior positions include Vice President at Discovery Senior Living, Regional Director of Operations at both Sunrise Senior Living and LCB Senior Living and Senior Executive Director at Atria Senior Living.

About National Healthcare Properties, Inc.

National Healthcare Properties, Inc. (Nasdaq: NHP) is a self-managed real estate investment trust focused on providing needs-based senior housing to serve a growing elderly population in the United States. Additional information about NHP can be found on its website at nhpreit.com.

Investor & Media Contact
Email: ir@nhpreit.com

Cautionary Statement Regarding Forward-Looking Statements

This press release may contain “forward-looking” statements as defined in the Private Securities Litigation Reform Act of 1995. Forward-looking statements generally can be identified by the use of terminology such as “believe,” “expect,” “anticipate,” “intend,” “plan,” “estimate,” “seek,” “will,” “may,” “should,” “predict,” “project,” “potential,” “continue” or the negatives of these terms or variations of them or similar expressions. Risks and uncertainties, the occurrence of which could adversely affect the Company’s business and cause actual results to differ materially from those expressed or implied in the forward-looking statements, include, but are not limited to, the following: changes in economic cycles generally and in the real estate and healthcare markets specifically; the success of the Company’s growth strategy, including its ability to successfully identify, complete and integrate new acquisitions; the Company’s ability to complete acquisitions or dispositions on the terms and timing the Company expects, or at all; changes to inflation and interest rates; competition in the real estate and healthcare markets; the Company’s ability to retain certain key personnel; legislative and regulatory changes in the healthcare and real estate industries; reductions or changes in reimbursement from third-party payors, including Medicare and Medicaid; discovery of previously undetected environmentally hazardous conditions; the Company’s ability to pay down, refinance, restructure or extend its indebtedness as it becomes due; system failures, cyber incidents or deficiencies in the Company’s cybersecurity systems; the availability of capital on favorable terms, or at all; the Company’s ability to remain qualified as a real estate investment trust for U.S. federal income tax purposes; and other risks and uncertainties described in the section titled Risk Factors of the Company’s most recent Annual Report on Form 10-K and all other filings with the Securities and Exchange Commission. Finally, the Company assumes no obligation to update or revise any forward-looking statements or to update the reasons why actual results could differ from those projected in any forward-looking statements.

Executive Snapshot:

Financial results:

  • Key metrics for the third quarter of 2026 compared to the third quarter of 2025:
    • Diluted earnings per share of $1.02 increased 18.6% compared to $0.86
    • Net interest income of $47.0 million, up 9.1% from $43.1 million
    • Net interest margin of 2.95%, up 16 basis points from 2.79%
    • Net income of $17.3 million increased 6.5% compared to $16.3 million
    • Average loans increased $238.1 million, or 4.6%
    • Average deposits increased $229.6 million, or 4.2%
  • Capital allocation and Stock Repurchase Program:
    • Increased dividend 5.3% to $0.40 per share, or $1.60 per share on an annualized basis
    • Purchased 13.2% of TrustCo outstanding common stock under the 2026 and 2025 Stock Repurchase Programs through the acquisition of over 1.5 million shares in the first nine months of 2026, following the purchase of 1 million shares in 2025, reinforcing a disciplined long-term capital allocation strategy
    • On pace to complete the repurchase of a total of three million shares, or 15.8%, of TrustCo common stock by the end of 2026

GLENVILLE, N.Y., Oct. 21, 2026 (GLOBE NEWSWIRE) —

TrustCo Bank Corp NY (TrustCo, NASDAQ: TRST) today announced financial results for the third quarter of 2026 highlighted by a continued increase in net interest income and sustained loan and deposit growth across core lending and deposit categories.   For the three months ended September 30, 2026, net interest income increased 9.1% year over year to $47.0 million. This was driven by the ongoing asset repricing across our loan portfolio at higher yields and effective execution of deposit growth and pricing strategies. For the three months ended September 30, 2026, net interest margin expanded to 2.95% from 2.79% in the prior year period. This resulted in third quarter 2026 net income of $17.3 million, or $1.02 diluted earnings per share, compared to net income of $16.3 million, or $0.86 diluted earnings per share, for the third quarter 2025; and contributed to net income of $50.6 million, or $2.91 diluted earnings per share, for the nine months ended September 30, 2026, compared to net income of $45.6 million, or $2.41 diluted earnings per share, for the nine months ended September 30, 2025.

Overview

Chairman, President, and CEO, Robert J. McCormick, said “Another quarter of solid financial performance is the product of TrustCo’s continued execution of tried and true banking principles that, quarter after quarter, continue to build positive momentum. Steady growth in both loans and deposits, coupled with favorable repricing of the Bank’s nearly $5.5 billion loan portfolio, have boosted net interest income to $47 million for the quarter, increased margin by 16 basis points, and driven return on average equity up 1.28% year over year, a 14% increase. Our management team has built a resilient balance sheet that can perform well in the current dynamic interest-rate environment, which efforts are supported by the entire organization’s focus on our relationship-based banking strategy. The ongoing repurchase of shares and regular payment of our recently-increased quarterly dividend work together to enhance shareholder value. With all of these factors coming together and trending favorably, we are optimistic about the Company’s ability to maintain positive momentum into 2027.”

Details

We have continued to see meaningful net income and net interest income improvement. The loan and investment portfolios of Trustco Bank (the “Bank”) continue to reprice upward as lower yielding assets mature and are replaced with higher rate loan originations and investment purchases, driving steady improvement in overall asset yields. We believe that this ongoing repricing reflects disciplined loan production aligned with current market conditions. Complementing this, the Bank maintains a strong liquidity position, driven by deposit growth while decreasing funding costs which underscores the Bank’s disciplined relationship banking strategy and the value customers place on stability and service.   We believe that these factors position the Bank to generate continued net income and net interest income growth in the coming quarters and deliver long-term value to shareholders. Net interest income was $47.0 million for the third quarter of 2026, an increase of $3.9 million, or 9.1%, compared to the third quarter of 2025, driven by loan growth at higher interest rates and a decrease in interest expense. The net interest margin for the third quarter of 2026 was 2.95%, up 16 basis points from 2.79% in the third quarter of 2025. The yield on interest-earning assets increased to 4.35% in the third quarter of 2026, up 10 basis points from 4.25% in the third quarter of 2025. The cost of interest bearing liabilities decreased to 1.79% in the third quarter of 2026, down 11 basis points from 1.90% in the third quarter of 2025.

Average loans were up $238.1 million, or 4.6%, in the third quarter of 2026 over the same period in 2025. Average residential loans and Home Equity Credit Lines (HECLs), our primary lending focus, were up $177.3 million, or 4.0%, and $50.0 million, or 11.4%, respectively, in the third quarter of 2026 over the same period in 2025. Average commercial loans also increased $13.5 million, or 4.3%, in the third quarter of 2026 over the same period in 2025. Loan growth in the third quarter of 2026 remained steady, driven by continued strength in core relationship lending. Credit quality metrics were stable. Following this period of sustained growth, TrustCo remains confident in the quality of its loan portfolio amid broader market concerns. We believe that our continued focus on strong underwriting within our loan portfolio and conservative lending standards positions us to manage credit risk effectively in the current environment.   The consistent growth in the loan portfolio will likely enhance net interest income in the quarters ahead. Average deposits were up $229.6 million, or 4.2%, for the third quarter of 2026 compared to the third quarter of 2025, primarily as a result of an increase in time deposits, interest bearing checking accounts, and demand deposits. The Bank’s ongoing emphasis on relationship banking, combined with competitive product offerings and digital capabilities, has contributed to a broadening deposit base that supports ongoing loan growth and expansion.

During the third quarter of 2026, the Bank remained focused on capital deployment and allocation, guided by a disciplined framework, with a dividend increase, and share repurchases, these serve as key tools to enhance shareholder value. This reflects our confidence in the long-term strength of the franchise and our focus on capital optimization. During the third quarter, the Bank declared an increased quarterly cash dividend of $0.40 per share, or $1.60 per share on an annualized basis. The declared dividend represents an increase of 5.3% over the prior dividend amount which continues the Banks commitment in paying dividends for over a century.   For the three and nine months ended September 30, 2026, TrustCo repurchased 500 thousand and 1.5 million shares, or 2.9% and 8.3%, respectively, of TrustCo’s outstanding common stock under its previously announced stock repurchase program, which authorizes TrustCo to repurchase up to two million shares, or 11.1%, of TrustCo’s outstanding common stock in 2026. We continue to believe that our approach ensures every dollar of capital is working to generate solid returns, strengthen customer relationships, and enhance shareholder value. As of September 30, 2026, our equity to asset ratio was 9.72%, compared to 10.90% as of September 30, 2025. Book value per share as of September 30, 2026 was $38.20, up 2.4% compared to $37.30 as of a year earlier.

Asset quality remains strong and has been consistent over the past twelve months. TrustCo recorded a provision for credit losses of $850 thousand in the third quarter of 2026, an increase of $600 thousand compared to the same period in 2025.   For the three months ended September 30, 2026, the provision for credit losses was the result of a provision for credit losses on loans of $1.05 million due to loan growth and changes in forward looking economic assumptions, and a benefit for credit losses on unfunded commitments of $200 thousand due to the seasonal decrease in the loan pipeline. Accordingly, increases in the overall provision expense are being driven by loan growth and changes in economic forecasts rather than the deterioration in underlying credit performance. The ratio of allowance for credit losses on loans to total loans was 1.01% and 1.00% as of September 30, 2026 and September 30, 2025, respectively. The allowance for credit losses on loans was $55.2 million as of September 30, 2026, compared to $51.9 million as of September 30, 2025. Nonperforming loans (NPLs) were $21.1 million as of September 30, 2026, compared to $18.5 million as of September 30, 2025. NPLs were 0.39% and 0.36% of total loans as of September 30, 2026 and September 30, 2025, respectively. The coverage ratio, or allowance for credit losses on loans to NPLs, was 261.8% as of September 30, 2026, compared to 280.8% as of September 30, 2025. Nonperforming assets (NPAs) were $22.3 million as of September 30, 2026, compared to $19.7 million as of September 30, 2025.   Asset quality metrics remain stable and well covered by reserves, reflecting the Bank’s conservative underwriting standards.

A conference call to discuss third quarter 2026 results will be held at 9:00 a.m. Eastern Time on October 22, 2026. Those wishing to participate in the call may dial toll-free for North America 1-833-461-5787, Meeting ID 638 789 515. The call will also be audio webcast at https://events.q4inc.com/attendee/638789515. The webcast replay will be available for one year at the same link.

About TrustCo Bank Corp NY

TrustCo Bank Corp NY is a $6.5 billion savings and loan holding company and through its subsidiary, Trustco Bank, operated 133 offices in New York, New Jersey, Vermont, Massachusetts, and Florida as of September 30, 2026.

In addition, the Bank’s Wealth Management Department offers a full range of investment services, retirement planning and trust and estate administration services. The common shares of TrustCo are traded on the NASDAQ Global Select Market under the symbol TRST.

Forward-Looking Statements

All statements in this news release and the related earnings call that are not historical are forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “anticipate,” “intend,” “plan,” “goal,” “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,” “likely,” “may,” “should,” “will,” “can” and similar references to future development, results or periods. Examples of forward-looking statements include, among others, statements we make regarding our expectations for our future performance, including our expectations regarding net income, net interest income and shareholder value for future quarters; expectations regarding our future momentum; the anticipated impact of our focus on underwriting within our loan portfolio and conservative lending standards; the expected impact of the continued repricing of our loan and investment portfolios, as well as our liquidity position, on our future net interest and net interest income; our balance sheet’s performance in future interest-rate environments; future overall asset yields; the amount of shares that we expect to repurchase in 2026; and the anticipated effects of our capital management strategy, including our stock repurchase program. Forward-looking statements are based on management’s current expectations, as well as certain assumptions and estimates made by, and information available to, management at the time the statements are made. Such forward-looking statements are subject to factors and uncertainties that could cause TrustCo’s actual results to differ materially from the views, beliefs and projections expressed in such statements. TrustCo wishes to caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. The following important factors, among others, in some cases have affected and in the future could affect TrustCo’s actual results and could cause TrustCo’s actual financial performance to differ materially from that expressed in any forward-looking statement: future changes in interest rates; external economic factors, such as changes in monetary policy, ongoing inflationary pressures and continued elevated prices; exposure to credit risk in our lending activities; the risk of weakness in residential real estate markets; our increasing commercial loan portfolio; the sufficiency of our allowance for credit losses on loans to cover actual loan losses; our ability to meet the cash flow requirements of our depositors or borrowers or to meet our operating cash needs to fund corporate expansion and other activities; claims and litigation pertaining to fiduciary responsibility and lender liability; the enforcement of federal cannabis laws and regulations and its impact on our ability to provide services in the cannabis industry; our dependency upon the services of the management team; our disclosure controls and procedures’ ability to prevent or detect errors or acts of fraud; the adequacy of our business continuity and disaster recovery plans; the effectiveness of our risk management framework; the impact of any expansion by us into new lines of business or new products and services; the rising popularity of alternative financial products, including fintech platforms, cryptocurrencies, money market funds, and digital wallets; an increase in the prevalence of fraud and other financial crimes; the impact of severe weather events and climate change on us and the communities we serve, including societal responses to climate change; environmental, social and governance risks and their impact on our reputation and relationships; the chance of a prolonged economic downturn, especially one affecting our geographic market area; instability in global economic conditions and geopolitical matters, including as a result of the conflict between the United States (U.S.) and Iran, as well as volatility in financial markets; the chance of a downgrade in the credit rating of the U.S. government or a default by the U.S. government; the soundness of other financial institutions; U.S. government shutdowns; fluctuations in the trust wealth management fees we receive as a result of investment performance; the impact of regulatory capital rules on our growth; changes in laws and regulations, including changes in cybersecurity or privacy regulations; our compliance with laws designed to protect consumers, including the Community Reinvestment Act and fair lending laws; restrictions on data collection and use; our compliance with the USA PATRIOT Act, Bank Secrecy Act, and other laws and regulations that could result in material fines or sanctions; changes in tax laws; limitations on our ability to pay dividends; TrustCo Realty Corp.’s ability to qualify as a real estate investment trust; changes in accounting standards; competition within our market areas; consumers and businesses’ use of non-banks to complete financial transactions; our reliance on third-party service providers; the impact of data breaches and cyber-attacks; the development and use of artificial intelligence; the impact of a failure in or breach of our operational or security systems or infrastructure, or those of third parties; the impact of an unauthorized disclosure of sensitive or confidential client or customer information; the impact of interruptions in the effective operation of our computer systems; the impact of anti-takeover provisions in our organizational documents; the impact of the manner in which we allocate capital; the impact of the actions of activist shareholders; and other risks and uncertainties set forth in our public filings made with the Securities and Exchange Commission (the “SEC”), including our Annual Report on Form 10-K for the year ended December 31, 2025, our Quarterly Report on Form 10-Q for the first and second quarters of 2026, our upcoming quarterly report on Form 10-Q for the third quarter of 2026, and future reports to be filed with the SEC. The forward-looking statements contained in this news release represent TrustCo management’s judgment as of the date of this news release. TrustCo disclaims, however, any intent or obligation to update forward-looking statements, either as a result of future developments, new information or otherwise, except as may be required by law.

TRUSTCO BANK CORP NY
GLENVILLE, NY
 
FINANCIAL HIGHLIGHTS
 
(dollars in thousands, except per share data)
(Unaudited)
    Three months ended
    9/30/2026   6/30/2026   9/30/2025
Summary of operations            
Net interest income   $ 47,039     $ 45,590     $ 43,119  
Provision for credit losses     850       650       250  
Net gains on equity securities     56       844       –  
Noninterest income, excluding net gains on equity securities     4,762       5,068       4,689  
Noninterest expense     28,019       28,333       26,242  
Net income     17,318       16,965       16,258  
             
Per share            
Net income per share:            
– Basic   $ 1.03     $ 0.98     $ 0.87  
– Diluted     1.02       0.98       0.86  
Cash dividends     0.40       0.38       0.38  
Book value at period end     38.20       38.53       37.30  
Market price at period end     54.29       54.91       36.30  
             
At period end            
Full time equivalent employees     740       742       738  
Full service banking offices     133       132       136  
             
Performance ratios            
Return on average assets     1.05 %     1.04 %     1.02 %
Return on average equity     10.57       10.22       9.29  
Efficiency ratio (GAAP)     54.03       55.01       54.89  
Adjusted Efficiency ratio (1)     54.11       55.71       54.87  
Net interest spread     2.56       2.48       2.35  
Net interest margin     2.95       2.87       2.79  
Dividend payout ratio     38.58       38.36       43.68  
             
Capital ratios at period end            
Consolidated equity to assets (GAAP)     9.72 %     10.05 %     10.90 %
Consolidated tangible equity to tangible assets (1)     9.71 %     10.05 %     10.89 %
             
Asset quality analysis at period end            
Nonperforming loans to total loans     0.39 %     0.40 %     0.36 %
Nonperforming assets to total assets     0.34       0.35       0.31  
Allowance for credit losses on loans to total loans     1.01       1.01       1.00  
Coverage ratio (2)     2.6 x     2.5 x     2.8 x
             
(1) Non-GAAP Financial Measure, see Non-GAAP Financial Measures Reconciliation.
(2) Calculated as allowance for credit losses on loans divided by total nonperforming loans.

FINANCIAL HIGHLIGHTS, Continued
 
(dollars in thousands, except per share data)
(Unaudited)
    Nine months ended
    09/30/26   09/30/25
Summary of operations        
Net interest income   $ 137,337     $ 125,238  
Provision for credit losses     2,450       1,200  
Net gains on equity securities     900       –  
Noninterest income, excluding net gains on equity securities     14,671       14,515  
Noninterest expense     83,334       78,794  
Net income     50,568       45,572  
         
Per share        
Net income per share:        
– Basic   $ 2.92     $ 2.41  
– Diluted     2.91       2.41  
Cash dividends     1.16       1.10  
Book value at period end     38.20       37.30  
Market price at period end     54.29       36.30  
         
Performance ratios        
Return on average assets     1.04 %     0.97 %
Return on average equity     10.15       8.84  
Efficiency ratio (GAAP)     54.50       56.38  
Adjusted Efficiency ratio (1)     54.72       55.98  
Net interest spread     2.49       2.28  
Net interest margin     2.89       2.71  
Dividend payout ratio     39.41       45.55  

(dollars in thousands, except per share data)
(Unaudited)
    Three months ended
    9/30/2026   6/30/2026   3/31/2026   12/31/2025   9/30/2025
Interest and dividend income:                    
Interest and fees on loans   $ 60,875     $ 58,757     $ 57,565     $ 56,886     $ 55,953  
Interest and dividends on securities available for sale:                    
U. S. government sponsored enterprises     86       111       149       350       599  
State and political subdivisions     –       –       –       –       1  
Mortgage-backed securities and collateralized mortgage obligations – residential     1,509       1,486       1,469       1,490       1,583  
Corporate bonds     820       776       694       536       265  
Small Business Administration – guaranteed participation securities     56       59       63       68       72  
Other securities     8       7       8       8       7  
Total interest and dividends on securities available for sale     2,479       2,439       2,383       2,452       2,527  
                     
Interest on held to maturity securities:                    
Mortgage-backed securities and collateralized mortgage obligations – residential     43       44       47       50       52  
Total interest on held to maturity securities     43       44       47       50       52  
                     
Federal Home Loan Bank stock     112       123       126       126       125  
                     
Interest on federal funds sold and other short-term investments     6,098       6,344       6,105       6,580       7,376  
Total interest income     69,607       67,707       66,226       66,094       66,033  
                     
Interest expense:                    
Interest on deposits:                    
Interest-bearing checking     642       551       533       501       483  
Savings     730       703       675       715       741  
Money market deposit accounts     1,597       1,631       1,552       1,810       2,065  
Time deposits     19,245       18,863       18,357       18,993       19,427  
Interest on short-term borrowings     354       369       401       340       198  
Total interest expense     22,568       22,117       21,518       22,359       22,914  
                     
Net interest income     47,039       45,590       44,708       43,735       43,119  
                     
Less: Provision for credit losses     850       650       950       400       250  
Net interest income after provision for credit losses     46,189       44,940       43,758       43,335       42,869  
                     
Noninterest income:                    
Trustco Financial Services income     2,059       1,980       2,135       1,950       1,967  
Fees for services to customers     2,409       2,487       2,340       2,192       2,429  
Net gains on equity securities     56       844       –       –       –  
Other     294       601       366       288       293  
Total noninterest income     4,818       5,912       4,841       4,430       4,689  
                     
Noninterest expenses:                    
Salaries and employee benefits     12,776       13,047       12,219       12,242       12,727  
Net occupancy expense     4,526       4,381       4,542       4,592       4,470  
Equipment expense     2,306       2,082       2,022       2,219       1,938  
Professional services     1,744       1,968       1,526       1,083       1,571  
Outsourced services     2,800       2,704       2,700       2,100       2,492  
Advertising expense     468       586       394       629       290  
FDIC and other insurance     1,104       1,101       1,153       1,135       1,052  
Other real estate (income) expense, net     (12 )     112       50       161       8  
Other     2,307       2,352       2,376       2,549       1,694  
Total noninterest expenses     28,019       28,333       26,982       26,710       26,242  
                     
Income before taxes     22,988       22,519       21,617       21,055       21,316  
Income taxes     5,670       5,554       5,332       5,490       5,058  
                     
Net income   $ 17,318     $ 16,965     $ 16,285     $ 15,565     $ 16,258  
                     
Net income per common share:                    
– Basic   $ 1.03     $ 0.98     $ 0.91     $ 0.85     $ 0.87  
                     
– Diluted     1.02       0.98       0.91       0.85       0.86  
                     
Weighted average basic shares (in thousands)     16,842       17,304       17,813       18,275       18,755  
Weighted average diluted shares (in thousands)     16,939       17,386       17,876       18,327       18,805  

CONSOLIDATED STATEMENTS OF INCOME, Continued
 
(dollars in thousands, except per share data)
(Unaudited)
    Nine months ended
    09/30/26   09/30/25
Interest and dividend income:        
Interest and fees on loans   $ 177,197     $ 163,960  
Interest and dividends on securities available for sale:        
U. S. government sponsored enterprises     346       1,809  
State and political subdivisions     –       1  
Mortgage-backed securities and collateralized mortgage obligations – residential     4,464       4,679  
Corporate bonds     2,290       735  
Small Business Administration – guaranteed participation securities     178       228  
Other securities     23       22  
Total interest and dividends on securities available for sale     7,301       7,474  
         
Interest on held to maturity securities:        
Mortgage-backed securities-residential     134       163  
Total interest on held to maturity securities     134       163  
         
Federal Home Loan Bank stock     361       405  
         
Interest on federal funds sold and other short-term investments     18,547       21,320  
Total interest income     203,540       193,322  
         
Interest expense:        
Interest on deposits:        
Interest-bearing checking     1,726       1,577  
Savings     2,108       2,208  
Money market deposit accounts     4,780       6,140  
Time deposits     56,465       57,605  
Interest on short-term borrowings     1,124       554  
Total interest expense     66,203       68,084  
         
Net interest income     137,337       125,238  
         
Less: Provision for credit losses     2,450       1,200  
Net interest income after provision for credit losses     134,887       124,038  
         
Noninterest income:        
Trustco Financial Services income     6,174       5,905  
Fees for services to customers     7,236       7,340  
Net gains on equity securities     900       –  
Other     1,261       1,270  
Total noninterest income     15,571       14,515  
         
Noninterest expenses:        
Salaries and employee benefits     38,042       36,497  
Net occupancy expense     13,449       13,542  
Equipment expense     6,410       5,800  
Professional services     5,238       5,183  
Outsourced services     8,204       7,652  
Advertising expense     1,448       955  
FDIC and other insurance     3,358       3,376  
Other real estate expense, net     150       558  
Other     7,035       5,231  
Total noninterest expenses     83,334       78,794  
         
Income before taxes     67,124       59,759  
Income taxes     16,556       14,187  
         
Net income   $ 50,568     $ 45,572  
         
Net income per common share:        
– Basic   $ 2.92     $ 2.41  
         
– Diluted     2.91       2.41  
         
Weighted average basic shares (in thousands)     17,317       18,912  
Weighted average diluted shares (in thousands)     17,398       18,947  

CONSOLIDATED STATEMENTS OF FINANCIAL CONDITION
 
(dollars in thousands)
(Unaudited)
    9/30/2026   6/30/2026   3/31/2026   12/31/2025   9/30/2025
ASSETS:                    
                     
Cash and due from banks   $ 42,914     $ 44,503     $ 43,165     $ 50,569     $ 42,026  
Federal funds sold and other short term investments     554,402       652,136       724,943       679,858       653,530  
Total cash and cash equivalents     597,316       696,639       768,108       730,427       695,556  
                   
Securities available for sale:                  
U. S. government sponsored enterprises     9,873       14,956       14,887       31,772       51,557  
States and political subdivisions     9       9       9       9       18  
Mortgage-backed securities and collateralized mortgage obligations – residential     196,688       203,601       205,209       206,290       215,466  
Small Business Administration – guaranteed participation securities     9,306       10,153       10,796       11,710       12,330  
Corporate bonds     77,434       73,804       69,137       59,932       39,800  
Other securities     713       718       708       705       701  
Total securities available for sale     294,023       303,241       300,746       310,418       319,872  
                     
Held to maturity securities:                    
Mortgage-backed securities and collateralized mortgage obligations-residential     3,640       3,842       4,097       4,339       4,593  
Total held to maturity securities     3,640       3,842       4,097       4,339       4,593  
                     
Federal Reserve Bank and Federal Home Loan Bank stock     6,756       6,756       6,601       6,601       6,601  
                   
Loans:                  
Commercial     332,406       322,439       316,763       313,443       311,491  
Residential mortgage loans     4,614,353       4,560,717       4,497,911       4,463,260       4,420,813  
Home equity line of credit     498,088       484,197       464,887       464,201       447,235  
Installment loans     9,439       9,882       10,617       11,556       12,231  
Loans, net of deferred net costs     5,454,286       5,377,235       5,290,178       5,252,460       5,191,770  
                   
Less: Allowance for credit losses on loans     55,162       54,082       52,994       52,205       51,891  
Net loans     5,399,124       5,323,153       5,237,184       5,200,255       5,139,879  
                     
Bank premises and equipment, net     42,266       42,273       41,071       40,707       39,718  
Operating lease right-of-use assets     32,715       33,872       33,305       33,638       35,291  
Other assets     118,220       115,137       116,767       114,315       107,514  
                   
Total assets   $ 6,494,060     $ 6,524,913     $ 6,507,879     $ 6,440,700     $ 6,349,024  
                   
LIABILITIES:                  
Deposits:                  
Demand   $ 817,555     $ 824,717     $ 811,637     $ 814,908     $ 795,508  
Interest-bearing checking     1,077,289       1,089,746       1,078,520       1,077,141       1,025,582  
Savings accounts     1,060,493       1,076,934       1,070,319       1,069,564       1,063,763  
Money market deposit accounts     429,555       438,799       442,760       457,389       455,488  
Time deposits     2,299,326       2,251,370       2,249,117       2,138,415       2,140,932  
Total deposits     5,684,218       5,681,566       5,652,353       5,557,417       5,481,273  
                   
Short-term borrowings     98,108       108,382       112,930       120,054       97,749  
Operating lease liabilities     35,075       36,361       35,920       36,391       38,180  
Accrued expenses and other liabilities     45,334       42,595       35,756       40,249       39,809  
                   
Total liabilities     5,862,735       5,868,904       5,836,959       5,754,111       5,657,011  
                   
SHAREHOLDERS’ EQUITY:                  
Capital stock     20,119       20,119       20,119       20,119       20,103  
Surplus     261,758       261,283       260,808       260,333       259,980  
Undivided profits     510,684       499,997       489,540       479,996       471,314  
Accumulated other comprehensive income, net of tax     76       6,967       8,241       10,024       2,955  
Treasury stock at cost     (161,312 )     (132,357 )     (107,788 )     (83,883 )     (62,339 )
                   
Total shareholders’ equity     631,325       656,009       670,920       686,589       692,013  
                     
Total liabilities and shareholders’ equity   $ 6,494,060     $ 6,524,913     $ 6,507,879     $ 6,440,700     $ 6,349,024  
                     
Outstanding shares (in thousands)     16,528       17,028       17,507       18,029       18,554  

NONPERFORMING ASSETS
                     
(dollars in thousands)
(Unaudited)
    9/30/2026   6/30/2026   3/31/2026   12/31/2025   9/30/2025
Nonperforming Assets                    
                     
New York and other states*                    
Loans in nonaccrual status:                    
Commercial   $ 2,008     $ 1,964     $ 1,968     $ 1,990     $ 292  
Real estate mortgage – 1 to 4 family     14,053       15,343       15,212       14,584       14,568  
Installment     19       37       43       29       30  
Total nonperforming loans     16,080       17,344       17,223       16,603       14,890  
Other real estate owned     1,183       1,234       1,364       1,394       1,234  
Total nonperforming assets   $ 17,263     $ 18,578     $ 18,587     $ 17,997     $ 16,124  
                     
Florida                    
Loans in nonaccrual status:                    
Commercial   $ –     $ –     $ –     $ –     $ –  
Real estate mortgage – 1 to 4 family     4,968       4,392       4,222       4,047       3,574  
Installment     19       16       20       22       13  
Total nonperforming loans     4,987       4,408       4,242       4,069       3,587  
Other real estate owned     –       –       –       –       –  
Total nonperforming assets   $ 4,987     $ 4,408     $ 4,242     $ 4,069     $ 3,587  
                     
Total                    
Loans in nonaccrual status:                    
Commercial   $ 2,008     $ 1,964     $ 1,968     $ 1,990     $ 292  
Real estate mortgage – 1 to 4 family     19,021       19,735       19,434       18,631       18,142  
Installment     38       53       63       51       43  
Total nonperforming loans     21,067       21,752       21,465       20,672       18,477  
Other real estate owned     1,183       1,234       1,364       1,394       1,234  
Total nonperforming assets   $ 22,250     $ 22,986     $ 22,829     $ 22,066     $ 19,711  
                     
                     
Quarterly Net (Recoveries) Chargeoffs                    
                     
New York and other states*                    
Commercial   $ –     $ –     $ 19     $ –     $ –  
Real estate mortgage – 1 to 4 family     (44 )     (72 )     (43 )     (33 )     (194 )
Installment     (1 )     (21 )     11       (13 )     (2 )
Total net chargeoffs (recoveries)   $ (45 )   $ (93 )   $ (13 )   $ (46 )   $ (196 )
                     
Florida                    
Commercial   $ –     $ –     $ (40 )   $ –     $ –  
Real estate mortgage – 1 to 4 family     –       –       –       –       –  
Installment     15       5       14       32       20  
Total net (recoveries) chargeoffs   $ 15     $ 5     $ (26 )   $ 32     $ 20  
                     
Total                    
Commercial   $ –     $ –     $ (21 )   $ –     $ –  
Real estate mortgage – 1 to 4 family     (44 )     (72 )     (43 )     (33 )     (194 )
Installment     14       (16 )     25       19       18  
Total net (recoveries) chargeoffs   $ (30 )   $ (88 )   $ (39 )   $ (14 )   $ (176 )
                     
                     
Asset Quality Ratios                    
                     
Total nonperforming loans (1)   $ 21,067     $ 21,752     $ 21,465     $ 20,672     $ 18,477  
Total nonperforming assets (1)     22,250       22,986       22,829       22,066       19,711  
Total net (recoveries) chargeoffs (2)     (30 )     (88 )     (39 )     (14 )     (176 )
                     
Allowance for credit losses on loans (1)     55,162       54,082       52,994       52,205       51,891  
                     
Nonperforming loans to total loans     0.39 %     0.40 %     0.41 %     0.39 %     0.36 %
Nonperforming assets to total assets     0.34 %     0.35 %     0.35 %     0.34 %     0.31 %
Allowance for credit losses on loans to total loans     1.01 %     1.01 %     1.00 %     0.99 %     1.00 %
Coverage ratio (1)     261.8 %     248.6 %     246.9 %     252.5 %     280.8 %
Annualized net (recoveries) chargeoffs to average loans (2)     0.00 %     -0.01 %     0.00 %     0.00 %     -0.01 %
Allowance for credit losses on loans to annualized net chargeoffs (2)     N/A       N/A       N/A       N/A       N/A  
 
* Includes New York, New Jersey, Vermont and Massachusetts.
(1) At period-end
(2) For the three-month period ended

DISTRIBUTION OF ASSETS, LIABILITIES AND SHAREHOLDERS’ EQUITY –
INTEREST RATES AND INTEREST DIFFERENTIAL
 
(dollars in thousands)                                
(Unaudited)   Three months ended   Three months ended
    September 30, 2026   September 30, 2025
    Average   Interest   Average   Average   Interest   Average
    Balance         Rate   Balance         Rate
Assets                                
                                 
Securities available for sale:                                
U. S. government sponsored enterprises   $ 10,977     $ 86     3.13 %   $ 69,294     $ 599     3.46 %
Mortgage backed securities and collateralized mortgage obligations – residential     217,254       1,509     2.75       237,092       1,583     2.65  
State and political subdivisions     9       –     6.77       18       1     6.77  
Corporate bonds     75,681       820     4.33       26,512       265     4.00  
Small Business Administration – guaranteed participation securities     10,440       56     2.14       13,385       72     2.15  
Other     717       8     4.46       700       7     4.00  
                                 
Total securities available for sale     315,078       2,479     3.15       347,001       2,527     2.91  
                                 
Federal funds sold and other short-term Investments     649,823       6,098     3.72       662,737       7,376     4.42  
                                 
Held to maturity securities:                                
Mortgage backed securities and collateralized mortgage obligations – residential     3,740       43     4.53       4,709       52     4.40  
                                 
Total held to maturity securities     3,740       43     4.53       4,709       52     4.40  
                                 
Federal Home Loan Bank stock     6,756       112     6.63       6,601       125     7.57  
                                 
Commercial loans     327,267       4,654     5.69       313,800       4,426     5.64  
Residential mortgage loans     4,586,955       48,286     4.21       4,409,645       44,089     4.00  
Home equity lines of credit     490,310       7,739     6.26       440,288       7,215     6.50  
Installment loans     9,182       196     8.46       11,842       223     7.48  
                                 
Loans, net of unearned income     5,413,714       60,875     4.49       5,175,575       55,953     4.32  
                                 
Total interest earning assets     6,389,111     $ 69,607     4.35       6,196,623     $ 66,033     4.25  
                                 
Allowance for credit losses on loans     (54,467 )                 (51,706 )            
Cash & non-interest earning assets     219,106                   208,701              
                                 
                                 
Total assets   $ 6,553,750                 $ 6,353,618              
                                 
                                 
Liabilities and shareholders’ equity                                
                                 
Deposits:                                
Interest bearing checking accounts   $ 1,092,564     $ 642     0.23 %   $ 1,035,366     $ 483     0.18 %
Money market accounts     442,480       1,597     1.43       464,334       2,065     1.76  
Savings     1,076,926       730     0.27       1,077,441       741     0.27  
Time deposits     2,288,063       19,245     3.34       2,125,920       19,427     3.63  
                                 
Total interest bearing deposits     4,900,033       22,214     1.80       4,703,061       22,716     1.92  
Short-term borrowings     102,386       354     1.37       87,348       198     0.90  
                                 
Total interest bearing liabilities     5,002,419     $ 22,568     1.79       4,790,409     $ 22,914     1.90  
                                 
Demand deposits     825,203                   792,621              
Other liabilities     75,989                   76,502              
Shareholders’ equity     650,139                   694,086              
                                 
Total liabilities and shareholders’ equity   $ 6,553,750                 $ 6,353,618              
                                 
Net interest income       $ 47,039               $ 43,119        
                                 
Net interest spread             2.56 %             2.35 %
                                 
                                 
Net interest margin (net interest income to total interest earning assets)             2.95 %             2.79 %
                                 
                                 
DISTRIBUTION OF ASSETS, LIABILITIES AND SHAREHOLDERS’ EQUITY –
INTEREST RATES AND INTEREST DIFFERENTIAL, Continued
                                 
(dollars in thousands)                                
(Unaudited)   Nine months ended   Nine Months Ended
    September 30, 2026   September 30, 2025
    Average   Interest   Average   Average   Interest   Average
    Balance         Rate   Balance         Rate
Assets                                
                                 
Securities available for sale:                                
U. S. government sponsored enterprises   $ 17,681       346     2.61 %   $ 72,461       1,809     3.33 %
Mortgage backed securities and collateralized mortgage obligations – residential     219,451       4,464     2.71       240,401       4,679     2.59  
State and political subdivisions     9       –     6.77       18       1     6.77  
Corporate bonds     70,395       2,290     4.34       30,696       735     3.19  
Small Business Administration – guaranteed participation securities     11,098       178     2.14       14,151       228     2.15  
Other     712       23     6.46       698       22     4.20  
                                 
Total securities available for sale     319,346       7,301     4.57       358,425       7,474     2.78  
                                 
Federal funds sold and other short-term Investments     668,926       18,547     3.71       641,793       21,320     4.44  
                                 
Held to maturity securities:                                
Mortgage backed securities and collateralized mortgage obligations – residential     3,972       134     4.50       4,969       163     4.37  
                                 
Total held to maturity securities     3,972       134     4.50       4,969       163     4.37  
                                 
Federal Home Loan Bank stock     6,704       361     10.77       6,567       405     8.22  
                                 
Commercial loans     320,738       13,565     5.64       306,091       12,851     5.60  
Residential mortgage loans     4,532,068       140,718     4.14       4,394,245       129,940     3.94  
Home equity lines of credit     476,358       22,297     6.26       427,830       20,480     6.40  
Installment loans     9,923       617     8.32       12,440       689     7.40  
                                 
Loans, net of unearned income     5,339,087       177,197     4.43       5,140,606       163,960     4.25  
                                 
Total interest earning assets     6,338,035       203,540     4.28       6,152,360       193,322     4.19  
                                 
Allowance for credit losses on loans     (53,483 )                 (50,991 )            
Cash & non-interest earning assets     220,871                   204,651              
                                 
                                 
Total assets   $ 6,505,423                 $ 6,306,020              
                                 
                                 
Liabilities and shareholders’ equity                                
                                 
Deposits:                                
Interest bearing checking accounts $   1,079,452       1,726     0.21 % $   1,037,598       1,577     0.20 %
Money market accounts     445,015       4,780     1.44       468,059       6,140     1.75  
Savings     1,072,414       2,108     0.26       1,084,712       2,208     0.27  
Time deposits     2,244,343       56,465     3.36       2,088,844       57,605     3.69  
                                 
Total interest bearing deposits     4,841,224       65,079     1.80       4,679,213       67,530     1.93  
Short-term borrowings     109,206       1,124     1.38       83,885       554     0.88  
                                 
Total interest bearing liabilities     4,950,430       66,203     1.79       4,763,098       68,084     1.91  
                                 
Demand deposits     814,465                   777,573              
Other liabilities     74,106                   76,372              
Shareholders’ equity     666,422                   688,977              
                                 
Total liabilities and shareholders’ equity $   6,505,423               $   6,306,020              
                                 
Net interest income         137,337                 125,238        
                                 
Net interest spread             2.49 %             2.28 %
                                 
                                 
Net interest margin (net interest income to total interest earning assets)             2.89 %             2.71 %


Non-GAAP Financial Measures Reconciliation

Tangible equity as a percentage of tangible assets at period end is a non-GAAP financial measure derived from GAAP-based amounts. We calculate tangible equity and tangible assets by excluding the balance of intangible assets from total shareholders’ equity and total assets, respectively. We calculate tangible equity as a percentage of tangible assets at period end by dividing tangible equity by tangible assets at period end. We believe that this is consistent with the treatment by bank regulatory agencies, which exclude intangible assets from the calculation of risk-based capital ratios. Additionally, we believe that this measure is important to many investors in the marketplace who are interested in relative changes from period to period in equity and total assets, each exclusive of changes in intangible assets.

Adjusted efficiency ratio is a non-GAAP measure of expense control relative to revenue from net interest income and non-interest income. We calculate the efficiency ratio by dividing total non-interest expense as determined under GAAP by the sum of net interest income and total non-interest income as determined under GAAP. We calculate the adjusted efficiency ratio by dividing total non-interest expenses as determined under GAAP, excluding other real estate expense, net, by the sum of net interest income and total non-interest income as determined under GAAP, excluding net gains on equity securities. We believe that this provides a reasonable measure of primary banking expenses relative to primary banking revenue. Additionally, we believe this measure is important to investors looking for a measure of efficiency in our productivity measured by the amount of revenue generated for each dollar spent.

We believe that these non-GAAP financial measures provide information that is important to investors and that is useful in understanding our financial results. Our management internally assesses our performance based, in part, on these measures. However, these non-GAAP financial measures are supplemental and not a substitute for an analysis based on GAAP measures. As other companies may use different calculations for these measures, this presentation may not be comparable to other similarly titled measures reported by other companies. A reconciliation of the non-GAAP measures of tangible equity as a percentage of tangible assets, and adjusted efficiency ratio to the most directly comparable GAAP measures is set forth below.  

NON-GAAP FINANCIAL MEASURES RECONCILIATION
                         
(dollars in thousands)                        
(Unaudited)                        
        9/30/2026   6/30/2026   9/30/2025        
Tangible Equity to Tangible Assets                        
                         
Equity (GAAP)       $ 631,325     $ 656,009     $ 692,013          
Less: Intangible assets         553       553       553          
Tangible equity (Non-GAAP)       $ 630,772     $ 655,456     $ 691,460          
                         
Total Assets (GAAP)       $ 6,494,060     $ 6,524,913     $ 6,349,024          
Less: Intangible assets         553       553       553          
Tangible assets (Non-GAAP)       $ 6,493,507     $ 6,524,360     $ 6,348,471          
                         
Consolidated Equity to Assets (GAAP)         9.72 %     10.05 %     10.90 %        
Consolidated Tangible Equity to Tangible Assets (Non-GAAP)         9.71 %     10.05 %     10.89 %        
                         
        Three months ended   Nine months ended
Efficiency and Adjusted Efficiency Ratios       9/30/2026   6/30/2026   9/30/2025   9/30/2026   9/30/2025
                         
Net interest income (GAAP)   A   $ 47,039     $ 45,590     $ 43,119     $ 137,337     $ 125,238  
Non-interest income (GAAP)   B     4,818       5,912       4,689       15,571       14,515  
Less: Net gains on equity securities   C     56       844       –       900       –  
Revenue used for efficiency ratio (Non-GAAP)   D   $ 51,801     $ 50,658     $ 47,808     $ 152,008     $ 139,753  
                         
Total noninterest expense (GAAP)   E   $ 28,019     $ 28,333     $ 26,242     $ 83,334     $ 78,794  
Less: Other real estate expense, net   F     (12 )     112       8       150       558  
Expense used for efficiency ratio (Non-GAAP)   G   $ 28,031     $ 28,221     $ 26,234     $ 83,184     $ 78,236  
                         
Efficiency Ratio (GAAP)   E/(A+B)     54.03 %     55.01 %     54.89 %     54.50 %     56.38 %
Adjusted Efficiency Ratio (Non-GAAP)   G/D     54.11 %     55.71 %     54.87 %     54.72 %     55.98 %

Subsidiary: Trustco Bank
   
Contact: Robert Leonard
  Executive Vice President
  (518) 381-3693
   
  Lauren A. McCormick
  Vice President, Treasurer, and
  Assistant Corporate Secretary
  (518) 381-3673

SOUTH SAN FRANCISCO, Calif., Oct. 21, 2026 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report third quarter results on November 4, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates.

The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at www.cytokinetics.com or directly at the following link: Cytokinetics Q3 2026 Earnings Conference Call. An archived replay of the webcast will be available via Cytokinetics’ website for six months.

About Cytokinetics

Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO® (aficamten) is a cardiac myosin inhibitor approved in the U.S., China, European Union, United Kingdom and Canada for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to submit a Supplemental New Drug Application in Q4 2026. Cytokinetics is also developing omecamtiv mecarbil, an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten, an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology.

For additional information about Cytokinetics, visit www.cytokinetics.com and follow us on X, LinkedIn, Facebook and YouTube.

Disclaimer

Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency.

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union, the United Kingdom and Canada.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757

New Hope Property

New Hope Property Exploration Results
New Hope Property Exploration Results

VANCOUVER, British Columbia, Oct. 21, 2026 (GLOBE NEWSWIRE) — Almadex Minerals Ltd. (“Almadex” or the “Company”) (TSX-V: “DEX”) is pleased to announce that it has expanded its claim block by staking at its wholly owned New Hope copper-gold porphyry exploration project in Arizona, USA. The new expanded New Hope claim block covers a broad area of high chargeability to the east of where the Company’s two-hole exploratory drill campaign was carried out (see Almadex news releases of April 1 and June 30th 2026). The Company is currently planning how a potential phase II drilling program might be conducted. The Company also reports that drilling operations have finished with one hole completed to 980 metres depth at the Company’s King copper-gold porphyry lithocap target in Colorado, USA. Samples have been submitted for assay and further information will be provided when all results have been received and compiled. A review of the New Hope project exploration results previously reported are provided below.

Highlights and Review of 2026 New Hope Results

  • Additional staking has been carried out to cover the large New Hope porphyry alteration zone defined by surface mapping and geophysics;
  • Magnetics and mapping suggest that the 2026 New Hope drilling previously reported is on the western edge of a 2.5 km x 0.75 km area of mapped phyllic and remnant lithocap porphyry alteration;
  • IP geophysics has extended the IP geophysical anomaly 1.95 km to the east of the line where both holes were drilled;
  • The Company’s completed and previously reported drill holes confirmed a large porphyry alteration system including the presence of a tourmaline bearing breccia pipe. Short zones of mineralisation with trace chalcopyrite were intersected in the second hole, including 6.00 metres @ 0.15% copper and 156 ppm molybdenum;
  • The Company is currently designing a potential phase II drilling program.

J Duane Poliquin, Chairman of Almadex commented, “The results from our past drilling, combined with the expanded geophysical target, highlight the scale of the porphyry system at New Hope. We are pleased to have expanded the claim position and are now evaluating options for a potential second phase of drilling.”

About the New Hope Project

The New Hope project in SW Arizona covers a large (2.5 by 0.75 km) area of mapped phyllic and remnant lithocap porphyry alteration. Drone-based magnetics suggest that the drilling to date is on the western edge of the alteration zone and a broad magnetics low associated with this alteration zone (see map attached). The recent IP lines surveyed to the east of the initial line supports this interpretation as the chargeability remains strong and open in this direction. Two diamond drill holes were completed in 2026, both drilled from the same pad (see Almadex news releases of April 1 and June 30th 2026). The first hole intersected andesite porphyry affected by moderate to strong phyllic alteration and zones of quartz veining to 384 meters when, after a zone of faulting and brecciation, propylitic to potassic alteration was encountered. Within the phyllic alteration, pyrite contents were up to an estimated 7% although no significant copper mineralisation was encountered. The second hole was collared from the same pad as the first hole and intersected an andesite intruded by late diorite dykes to 483 metres at which point a large breccia body was encountered. The andesite is affected by phyllic, argillic and propylitic alteration with pyrite contents up to 5%, and the diorite by potassic to propylitic alteration. The breccia body is comprised of clasts from a range of largely intrusive lithologies affected by silicification, phyllic and propylitic alteration. The matrix is often silicified with pyrite and abundant tourmaline. Veins of tourmaline and pyrite also crosscut the breccia. Two zones of copper mineralisation with traces of chalcopyrite were intersected:

498.00 to 504.00 m (6.00 m) @ 0.15 % Cu and 156 ppm Mo (fault zone with traces of chalcopyrite, sphalerite and galena)

Including 500.00 to 502.00 m (2.00 m) @ 0.34% Cu and 326 ppm Mo

        778.00 to 780.00 m (2.00 m) @ 0.14% Cu and 5 ppm Mo (tourmaline bearing breccia)

The two holes confirm the presence of a large porphyry alteration system. Tourmaline bearing breccias are common in porphyry environments and are often a late overprinting feature. The breccia fragments and associated alteration suggest that the drilling to date may be on the periphery of the core to a porphyry system which has not yet been intersected. The presence of copper is encouraging, as is the expansion of the IP anomaly to the east where previous mapping has traced phyllic alteration.

Qualified Persons

Morgan J Poliquin, PhD, PEng, the President and CEO of Almadex and a Qualified Person (“QP”) as defined by National Instrument 43-101 (“NI 43-101”), has reviewed and approved the scientific and technical contents of this news release. Daniel Santamaria, P.Geo. and a Qualified Person as defined by NI 43-101, is the QP for the New Hope drilling project and has reviewed and approved the contents of this news release. The drilling program and core sampling reported were conducted under his supervision.

Blanks, field duplicates and certified standards were inserted into the sample stream as part of Almadex’s quality assurance and control program. True widths are not possible to calculate at this time for the drill intercepts described, as they occur in zones of complex veining and brecciation. The analyses reported were carried out at ALS Chemex Laboratories of Tucson and North Vancouver using industry standard analytical techniques. For copper and molybdenum, samples are analysed by Inductively Coupled Plasma – Atomic Emission Spectroscopy (“ICP-AES”), with four acid digestion. Samples that return values greater than 10,000 g/t copper using this technique are then re-analysed by HF-HNO3-HCLO4 digestion with HCL leach and ICP-AES finish. The IP geophysical survey described was carried out using the Company’s in-house equipment, a 5 kW GDD transmitter and Iris Elrec-6 receivers using a 100 m dipole in a pole-dipole array on 8 levels. Pseudo sections were prepared and the data was inverted using RES2DINV software.

About Almadex

Almadex Minerals Ltd. is a mineral exploration company focused on base and precious metals in the western United States. The Company owns several portable diamond drill rigs, enabling it to conduct cost effective first pass exploration drilling in house.

On behalf of the Board of Directors,

“Morgan J. Poliquin”        

Morgan J. Poliquin, PhD, Peng

President and CEO

Almadex Minerals Ltd.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within it, other than statements of historical fact, are to be considered forward looking. Forward-looking statements in this news release include, among other things, exploration and drilling plans and timing of the New Hope and King exploration drilling programs. Although the Company believes the expectations expressed in such forward looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, permitting, continued availability of capital and financing, equipment availability and general economic, market or business conditions. The foregoing list of assumptions is not exhaustive. There can be no assurances that forward-looking statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. The Company does not assume any obligation to update any forward-looking statements, other than as required pursuant to applicable securities laws. This news release also does not constitute an offer to sell or a solicitation of an offer to sell any securities in the United States. The securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/19970da0-0d63-4692-9ca9-b3fc9551464c

CONTACT: Contact Information:
Almadex Minerals Ltd.
Tel. 604.689.7644
Email: info@almadexminerals.com
http://www.almadexminerals.com/

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.